{
  "$schema": "folio-library-document/v1",
  "id": "10665-249154",
  "title": "The use of loop-mediated isothermal amplification (TB-LAMP) for the diagnosis of pulmonary tuberculosis: policy guidance",
  "variant": "pdf",
  "pages": 52,
  "tocSource": "inferred",
  "tocMethod": "contents",
  "toc": [
    {
      "level": 1,
      "title": "Executive summary",
      "number": null,
      "page": 13,
      "pageLabel": "1",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-000-executive-summary"
    },
    {
      "level": 1,
      "title": "Background",
      "number": "1",
      "page": 15,
      "pageLabel": "3",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-001-1-background"
    },
    {
      "level": 1,
      "title": "Methods",
      "number": "2",
      "page": 19,
      "pageLabel": "7",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-002-2-methods"
    },
    {
      "level": 2,
      "title": "Evidence synthesis",
      "number": "2.1",
      "page": 19,
      "pageLabel": "7",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-003-21-evidence-synthesis"
    },
    {
      "level": 2,
      "title": "Criteria for considering studies for this review",
      "number": "2.2",
      "page": 19,
      "pageLabel": "7",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-004-22-criteria-for-considering-studies-for-this-rev"
    },
    {
      "level": 2,
      "title": "Data collection and analysis",
      "number": "2.3",
      "page": 21,
      "pageLabel": "9",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-005-23-data-collection-and-analysis"
    },
    {
      "level": 2,
      "title": "Guideline Development Group meeting",
      "number": "2.4",
      "page": 22,
      "pageLabel": "10",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-006-24-guideline-development-group-meeting"
    },
    {
      "level": 2,
      "title": "External Review Group",
      "number": "2.5",
      "page": 22,
      "pageLabel": "10",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-007-25-external-review-group"
    },
    {
      "level": 1,
      "title": "Scope",
      "number": "3",
      "page": 23,
      "pageLabel": "11",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-008-3-scope"
    },
    {
      "level": 2,
      "title": "Target audience",
      "number": "3.1",
      "page": 23,
      "pageLabel": "11",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-009-31-target-audience"
    },
    {
      "level": 1,
      "title": "Evidence base for policy formulation",
      "number": "4",
      "page": 24,
      "pageLabel": "12",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-010-4-evidence-base-for-policy-formulation"
    },
    {
      "level": 2,
      "title": "Assessment of methodological quality",
      "number": "4.1",
      "page": 27,
      "pageLabel": "15",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-011-41-assessment-of-methodological-quality"
    },
    {
      "level": 1,
      "title": "Results of the systematic review",
      "number": "5",
      "page": 29,
      "pageLabel": "17",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-012-5-results-of-the-systematic-review"
    },
    {
      "level": 2,
      "title": "Accuracy of TB-LAMP as a replacement test for smear microscopy",
      "number": "5.1",
      "page": 29,
      "pageLabel": "17",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-013-51-accuracy-of-tb-lamp-as-a-replacement-test-for"
    },
    {
      "level": 2,
      "title": "Accuracy of TB-LAMP as a replacement test for smear microscopy in persons living with HIV",
      "number": "5.2",
      "page": 31,
      "pageLabel": "19",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-014-52-accuracy-of-tb-lamp-as-a-replacement-test-for"
    },
    {
      "level": 2,
      "title": "Accuracy of TB-LAMP as an add-on test following smear microscopy for smear-negative adults",
      "number": "5.3",
      "page": 32,
      "pageLabel": "20",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-015-53-accuracy-of-tb-lamp-as-an-add-on-test-followi"
    },
    {
      "level": 2,
      "title": "Accuracy of TB-LAMP compared with Xpert MTB/RIF assay for detecting pulmonary TB",
      "number": "5.4",
      "page": 34,
      "pageLabel": "22",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-016-54-accuracy-of-tb-lamp-compared-with-xpert-mtbri"
    },
    {
      "level": 1,
      "title": "TB-LAMP is used to detect pulmonary TB among all adults and among HIV-positive adults",
      "number": null,
      "page": 36,
      "pageLabel": "24",
      "confidence": 0.75,
      "evidence": [
        "contents",
        "body"
      ],
      "source": "inferred",
      "section": "sec-017-tb-lamp-is-used-to-detect-pulmonary-tb-among-all"
    },
    {
      "level": 1,
      "title": "Cost-effectiveness analysis",
      "number": "6",
      "page": 37,
      "pageLabel": "25",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-018-6-cost-effectiveness-analysis"
    },
    {
      "level": 1,
      "title": "Summary: from evidence to recommendations",
      "number": "7",
      "page": 38,
      "pageLabel": "26",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-019-7-summary-from-evidence-to-recommendations"
    },
    {
      "level": 2,
      "title": "TB-LAMP for the detection of pulmonary TB in all adults",
      "number": "7.1",
      "page": 38,
      "pageLabel": "26",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-020-71-tb-lamp-for-the-detection-of-pulmonary-tb-in"
    },
    {
      "level": 2,
      "title": "TB-LAMP for the detection of pulmonary TB in adults living with HIV",
      "number": "7.2",
      "page": 38,
      "pageLabel": "26",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-021-72-tb-lamp-for-the-detection-of-pulmonary-tb-in"
    },
    {
      "level": 2,
      "title": "TB-LAMP as an add-on test for detecting of pulmonary TB in adults following negative smear microscopy",
      "number": "7.3",
      "page": 39,
      "pageLabel": "27",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-022-73-tb-lamp-as-an-add-on-test-for-detecting-of-pu"
    },
    {
      "level": 2,
      "title": "TB-LAMP as a replacement test for the Xpert MTB/RIF assay for detecting pulmonary TB in adults",
      "number": "7.4",
      "page": 39,
      "pageLabel": "27",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-023-74-tb-lamp-as-a-replacement-test-for-the-xpert-m"
    },
    {
      "level": 1,
      "title": "WHO policy recommendations",
      "number": "8",
      "page": 41,
      "pageLabel": "29",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-024-8-who-policy-recommendations"
    },
    {
      "level": 1,
      "title": "Implementation considerations",
      "number": "9",
      "page": 42,
      "pageLabel": "30",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-025-9-implementation-considerations"
    },
    {
      "level": 1,
      "title": "Plans for disseminating WHO’s guidance on TB-LAMP",
      "number": "10",
      "page": 43,
      "pageLabel": "31",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-026-10-plans-for-disseminating-whos-guidance-on-tb-l"
    },
    {
      "level": 1,
      "title": "Research needs",
      "number": "11",
      "page": 44,
      "pageLabel": "32",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-027-11-research-needs"
    },
    {
      "level": 1,
      "title": "Annexes",
      "number": "12",
      "page": 45,
      "pageLabel": "33",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-028-12-annexes"
    },
    {
      "level": 1,
      "title": "References to studies for the systematic review of the diagnostic accuracy of TB-LAMP",
      "number": "Annex 1",
      "page": 45,
      "pageLabel": "33",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-029-annex-1-references-to-studies-for-the-systematic"
    },
    {
      "level": 1,
      "title": "GRADE Evidence Profiles",
      "number": "Annex 2",
      "page": 47,
      "pageLabel": "35",
      "confidence": 0.55,
      "evidence": [
        "contents",
        "number"
      ],
      "source": "inferred",
      "section": "sec-030-annex-2-grade-evidence-profiles"
    },
    {
      "level": 1,
      "title": "Abstracts for unpublished studies",
      "number": "Annex 3",
      "page": 50,
      "pageLabel": "38",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-031-annex-3-abstracts-for-unpublished-studies"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 13,
      "labelStart": "i",
      "labelEnd": "1",
      "words": 2122,
      "summary": {
        "text": "The front matter of WHO policy guidance on using loop-mediated isothermal amplification (TB-LAMP) to diagnose pulmonary tuberculosis. It includes the cover, cataloguing data with ISBN, copyright and disclaimer notices, and a table of contents covering methods, results of the systematic review, cost-effectiveness and recommendations. It also contains acknowledgements and lists of contributors. It ends with the declarations of interest of Guideline Development Group members and the planned review date of 2020.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tb-lamp sensitivity",
          "heading": false
        },
        {
          "term": "san francisco",
          "heading": false
        },
        {
          "term": "tb-lamp compared",
          "heading": false
        },
        {
          "term": "sputum-smear microscopy",
          "heading": false
        },
        {
          "term": "loop-mediated isothermal",
          "heading": false
        },
        {
          "term": "smear microscopy",
          "heading": false
        },
        {
          "term": "supranational reference",
          "heading": false
        },
        {
          "term": "isothermal amplification",
          "heading": false
        }
      ],
      "extract": "The use of loop-mediated isothermal amplification (TB-LAMP) for the diagnosis of pulmonary tuberculosis POLICY GUIDANCE EARLY DIAGNOSIS LOOP-MEDIATED ISOTHERMAL AMPLIFICATION DNA TUBERCULOSIS TB-LAMP NEW DIAGNOSTIC TEST MOLECULAR DIAGNOSTICS PULMONARY TB RECOMMENDATIONS DIAGNOSIS MOLECULAR DIAGNOSTICS RAPID MOLECULAR TEST M. TUBERCULOSIS COMPLEX THE STRATEGY END TB The use of loop-mediated isothermal amplification",
      "extractCut": true,
      "blocks": [
        "library/10665-249154/blocks/prose-sec-front-matter"
      ]
    },
    {
      "id": "sec-000-executive-summary",
      "number": null,
      "title": "Executive summary",
      "level": 1,
      "pageStart": 13,
      "pageEnd": 15,
      "labelStart": "1",
      "labelEnd": "3",
      "words": 797,
      "summary": {
        "text": "Summarizes the TB-LAMP policy guidance, explaining the End TB Strategy's call for early diagnosis and how the manual LAMP assay works and can be read under ultraviolet light. It recounts the 2012 Guideline Development Group review and the newer evidence assessment. It then states the conditional recommendations for using TB-LAMP instead of, or after, sputum-smear microscopy, together with remarks limiting their scope.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "sputum-smear microscopy",
          "heading": false
        },
        {
          "term": "symptoms consistent",
          "heading": false
        },
        {
          "term": "detecting pulmonary",
          "heading": false
        },
        {
          "term": "smear microscopy",
          "heading": false
        },
        {
          "term": "executive summary",
          "heading": true
        },
        {
          "term": "tb-lamp",
          "heading": false
        },
        {
          "term": "microscopy among",
          "heading": false
        },
        {
          "term": "eiken chemical",
          "heading": false
        }
      ],
      "extract": "Executive summary Background World Health Organization’s (WHO’s) End TB Strategy calls for the early diagnosis of tuberculosis (TB) and for universal drug-susceptibility testing, highlighting the critical role of laboratories in the post-2015 era in rapidly and accurately detecting TB and drug resistance.1 Molecular assays based on nucleic acid amplification techniques, such as polymerase chain reaction, have been",
      "extractCut": true
    },
    {
      "id": "sec-001-1-background",
      "number": "1",
      "title": "Background",
      "level": 1,
      "pageStart": 15,
      "pageEnd": 19,
      "labelStart": "3",
      "labelEnd": "7",
      "words": 1121,
      "summary": {
        "text": "Sets out the background to TB-LAMP, noting that a large share of TB cases worldwide go undetected and that new diagnostics are a priority. It describes the commercial Eiken assay, its modest infrastructure needs and its history of WHO review. It then walks through the TB-LAMP workflow, from sample preparation and heating to visual reading of fluorescence and waste disposal.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "heating tube",
          "heading": false
        },
        {
          "term": "reaction tube",
          "heading": false
        },
        {
          "term": "heating block",
          "heading": false
        },
        {
          "term": "loop primers",
          "heading": false
        },
        {
          "term": "double-stranded dna",
          "heading": false
        },
        {
          "term": "ultraviolet light",
          "heading": false
        },
        {
          "term": "isothermal amplification",
          "heading": false
        },
        {
          "term": "dna synthesis",
          "heading": false
        }
      ],
      "extract": "Tuberculosis (TB) remains a large-scale public health problem. Key global priorities for TB care and control include improving case-detection and detecting patients earlier, particularly patients with smear-negative TB disease. In 2014, only 63% (6 million) of an estimated 9.6 million people who developed TB were reported to WHO, meaning that globally 37% of the estimated cases of TB are undetected. WHO has",
      "extractCut": true
    },
    {
      "id": "sec-002-2-methods",
      "number": "2",
      "title": "Methods",
      "level": 1,
      "pageStart": 19,
      "pageEnd": 19,
      "labelStart": "7",
      "labelEnd": "7",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-003-21-evidence-synthesis",
      "number": "2.1",
      "title": "Evidence synthesis",
      "level": 2,
      "pageStart": 19,
      "pageEnd": 19,
      "labelStart": "7",
      "labelEnd": "7",
      "words": 310,
      "summary": {
        "text": "Explains that the GRADE approach and PICO-framed questions were used to assess the evidence on TB-LAMP. It lists the four review questions on accuracy versus microscopy, use as an add-on test, comparison with Xpert MTB/RIF, and rates of invalid results.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pico questions",
          "heading": false
        },
        {
          "term": "detecting pulmonary",
          "heading": false
        },
        {
          "term": "sputum-smear microscopy",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "microscopy compared",
          "heading": false
        },
        {
          "term": "tb-lamp",
          "heading": false
        },
        {
          "term": "diagnostic tests",
          "heading": false
        },
        {
          "term": "evidence",
          "heading": true
        }
      ],
      "extract": "In accordance with WHO’s standards for assessing evidence when formulating policy recommendations, the GRADE approach (Grading of Recommendations Assessment, Development and Evaluation, see http://www.gradeworkinggroup.org/) was used. GRADE provides a structured framework for evaluating the accuracy of diagnostic tests and their impact on patients and public health. The evaluation used the GRADE system to determine",
      "extractCut": true
    },
    {
      "id": "sec-004-22-criteria-for-considering-studies-for-this-rev",
      "number": "2.2",
      "title": "Criteria for considering studies for this review",
      "level": 2,
      "pageStart": 19,
      "pageEnd": 21,
      "labelStart": "7",
      "labelEnd": "9",
      "words": 777,
      "summary": {
        "text": "Defines which TB-LAMP studies were eligible for the systematic review, including prospective studies after 2012 in intermediate- and high-burden settings and a supplementary literature search. It lists exclusion criteria for studies and individual participants and describes the culture-based reference standards and smear microscopy definitions used.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "ziehl neelsen",
          "heading": false
        },
        {
          "term": "fluorescence microscopy",
          "heading": false
        },
        {
          "term": "direct ziehl",
          "heading": false
        },
        {
          "term": "speciation testing",
          "heading": false
        },
        {
          "term": "rapid speciation",
          "heading": false
        },
        {
          "term": "mycobacterial culture",
          "heading": false
        },
        {
          "term": "cultures performed",
          "heading": false
        },
        {
          "term": "culture confirmed",
          "heading": false
        }
      ],
      "extract": "The review included all prospective studies that evaluated the use of TB-LAMP on sputum samples from adults with signs and symptoms consistent with pulmonary TB that were conducted in settings with an intermediate or high burden of TB. All included studies were conducted after 1 January 2012, using the final, design-locked TB-LAMP protocol that had been modified by the manufacturer. Twenty studies were identified,",
      "extractCut": true
    },
    {
      "id": "sec-005-23-data-collection-and-analysis",
      "number": "2.3",
      "title": "Data collection and analysis",
      "level": 2,
      "pageStart": 21,
      "pageEnd": 22,
      "labelStart": "9",
      "labelEnd": "10",
      "words": 570,
      "summary": {
        "text": "Describes how individual-level data were obtained from FIND-affiliated and other TB-LAMP studies, listing the minimum and optional variables collected. It then outlines how accuracy, incremental yield and invalid result rates were calculated and how heterogeneity was assessed.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "microsoft excel",
          "heading": false
        },
        {
          "term": "false negatives",
          "heading": false
        },
        {
          "term": "false positives",
          "heading": false
        },
        {
          "term": "true negatives",
          "heading": false
        },
        {
          "term": "unnecessary treatment",
          "heading": false
        },
        {
          "term": "tb-lamp",
          "heading": false
        },
        {
          "term": "smear microscopy",
          "heading": false
        },
        {
          "term": "epidata",
          "heading": false
        }
      ],
      "extract": "For studies conducted by or funded through FIND, study protocols, inclusion criteria and definitions were provided by FIND along with data on individual participants. Further review of the individual- level data was performed to verify that the study and individual participants met eligibility criteria. For studies not affiliated with FIND, individual-level data were requested from the investigators and reviewed by",
      "extractCut": true
    },
    {
      "id": "sec-006-24-guideline-development-group-meeting",
      "number": "2.4",
      "title": "Guideline Development Group meeting",
      "level": 2,
      "pageStart": 22,
      "pageEnd": 22,
      "labelStart": "10",
      "labelEnd": "10",
      "words": 95,
      "summary": {
        "text": "Notes that a WHO Guideline Development Group met in January 2016 to review 20 new TB-LAMP studies, 13 of which met inclusion criteria, and outlines the roles of the methodologist and Steering Group.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "gdg meeting",
          "heading": false
        },
        {
          "term": "steering group",
          "heading": false
        },
        {
          "term": "guideline",
          "heading": true
        }
      ],
      "extract": "Following the initial GDG meeting on TB-LAMP in 2012, a GDG meeting was convened by WHO in January 2016 to review the evidence from 20 new studies, of which 13 studies conducted in 11 countries met the inclusion criteria. The guideline methodologist participated in the initial planning and scoping and in the development of the key questions for the GDG meeting but did not participate in the meeting. The WHO Steering",
      "extractCut": true
    },
    {
      "id": "sec-007-25-external-review-group",
      "number": "2.5",
      "title": "External Review Group",
      "level": 2,
      "pageStart": 22,
      "pageEnd": 23,
      "labelStart": "10",
      "labelEnd": "11",
      "words": 248,
      "summary": {
        "text": "Describes how the Steering Group handled interests, PICO questions and the consensus process for the TB-LAMP recommendations, and how an External Review Group of laboratory experts found no major errors or concerns in the guidance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "review group",
          "heading": true
        },
        {
          "term": "external review",
          "heading": true
        },
        {
          "term": "gdg meeting",
          "heading": false
        },
        {
          "term": "steering group",
          "heading": false
        },
        {
          "term": "tables showing",
          "heading": false
        },
        {
          "term": "pico questions",
          "heading": false
        },
        {
          "term": "decisions",
          "heading": false
        },
        {
          "term": "recommendations",
          "heading": false
        }
      ],
      "extract": "Interest and for organizing the GDG meetings. A brief biography of each GDG member was made available for public scrutiny on the website of the WHO Global TB Programme (http://www.who. int/tb/areas-of-work/laboratory/policy_statements/en/) 2 weeks prior to the GDG meeting. PICO questions were drafted by the Steering Group and were presented to the GDG for discussion and modification. The Steering Group also prepared",
      "extractCut": true
    },
    {
      "id": "sec-008-3-scope",
      "number": "3",
      "title": "Scope",
      "level": 1,
      "pageStart": 23,
      "pageEnd": 23,
      "labelStart": "11",
      "labelEnd": "11",
      "words": 76,
      "summary": {
        "text": "States that the guidance summarizes evidence and recommendations on using TB-LAMP for pulmonary TB in symptomatic adults and should be read with WHO's 2015 framework for implementing TB diagnostics.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "scope",
          "heading": true
        },
        {
          "term": "conjunction",
          "heading": false
        },
        {
          "term": "tb-lamp",
          "heading": false
        }
      ],
      "extract": "3. Scope This document provides a pragmatic summary of the evidence and recommendations on using TB-LAMP to diagnose pulmonary TB in adults with signs and symptoms consistent with TB. It should be read in conjunction with the WHO’s 2015 framework for implementing TB diagnostics, which provides guidance on implementing the diagnostic tools and methods approved by WHO within the context of a country’s infrastructure,",
      "extractCut": true
    },
    {
      "id": "sec-009-31-target-audience",
      "number": "3.1",
      "title": "Target audience",
      "level": 2,
      "pageStart": 23,
      "pageEnd": 24,
      "labelStart": "11",
      "labelEnd": "12",
      "words": 105,
      "summary": {
        "text": "Identifies the intended users of the TB-LAMP guidance, from clinicians and laboratory directors to donors, procurement officers and programme planners.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mobilizing",
          "heading": false
        },
        {
          "term": "laboratory",
          "heading": false
        },
        {
          "term": "advisers",
          "heading": false
        },
        {
          "term": "directors",
          "heading": false
        }
      ],
      "extract": "This guidance is intended to be used by clinicians treating patients with TB, and managers and laboratory directors working in TB programmes, in coordination with external laboratory consultants, donor agencies, technical advisers, laboratory technicians, procurement officers for laboratory equipment, service providers in the private sector, relevant government sectors, and implementation partners that are involved",
      "extractCut": true
    },
    {
      "id": "sec-010-4-evidence-base-for-policy-formulation",
      "number": "4",
      "title": "Evidence base for policy formulation",
      "level": 1,
      "pageStart": 24,
      "pageEnd": 27,
      "labelStart": "12",
      "labelEnd": "15",
      "words": 1110,
      "summary": {
        "text": "Describes the evidence base for the TB-LAMP recommendations: of 20 studies identified, 13 in 11 countries met inclusion criteria, many of them unpublished. It explains the role of FIND in conducting or sponsoring most studies and gives participant numbers and study periods. Tables summarize study characteristics such as setting, HIV prevalence and reference standards.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nam rfa",
          "heading": false
        },
        {
          "term": "ivoire rfa",
          "heading": false
        },
        {
          "term": "fresh processed",
          "heading": false
        },
        {
          "term": "fresh direct",
          "heading": false
        },
        {
          "term": "frozen processed",
          "heading": false
        },
        {
          "term": "fluorescence microscopy",
          "heading": false
        },
        {
          "term": "liquid culture",
          "heading": false
        },
        {
          "term": "clinic direct",
          "heading": false
        }
      ],
      "extract": "Of the 20 studies identified that evaluated TB-LAMP, 13 studies conducted in 11 countries met the criteria for inclusion in the systematic review (Fig. 4). Six studies were excluded because it was unclear whether participants had been receiving TB treatment within 60 days prior to enrolment. One study was excluded because rapid speciation testing on positive mycobacterial cultures was not performed. (Annex 1",
      "extractCut": true
    },
    {
      "id": "sec-011-41-assessment-of-methodological-quality",
      "number": "4.1",
      "title": "Assessment of methodological quality",
      "level": 2,
      "pageStart": 27,
      "pageEnd": 29,
      "labelStart": "15",
      "labelEnd": "17",
      "words": 713,
      "summary": {
        "text": "Reports the QUADAS-2 appraisal of the included TB-LAMP studies, judging overall risk of bias as high mainly because of the culture reference standard, unclear patient selection and flow and timing problems. A table gives each study's risk-of-bias and applicability ratings, and notes explain the judgements.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nam rfa",
          "heading": false
        },
        {
          "term": "madagascar rfa",
          "heading": false
        },
        {
          "term": "india rfa",
          "heading": false
        },
        {
          "term": "ivoire rfa",
          "heading": false
        },
        {
          "term": "tanzania rfa",
          "heading": false
        },
        {
          "term": "uganda rfa",
          "heading": false
        },
        {
          "term": "viet nam",
          "heading": false
        },
        {
          "term": "haiti unpublished",
          "heading": false
        }
      ],
      "extract": "The quality of the included studies was appraised with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool.10 QUADAS-2 consists of four domains: patient selection, index test, reference standard, and flow and timing. All domains were assessed for the potential for risk of bias, and the first three domains for concerns regarding applicability. Signalling questions in each domain were used to form",
      "extractCut": true
    },
    {
      "id": "sec-012-5-results-of-the-systematic-review",
      "number": "5",
      "title": "Results of the systematic review",
      "level": 1,
      "pageStart": 29,
      "pageEnd": 29,
      "labelStart": "17",
      "labelEnd": "17",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-013-51-accuracy-of-tb-lamp-as-a-replacement-test-for",
      "number": "5.1",
      "title": "Accuracy of TB-LAMP as a replacement test for smear microscopy",
      "level": 2,
      "pageStart": 29,
      "pageEnd": 31,
      "labelStart": "17",
      "labelEnd": "19",
      "words": 894,
      "summary": {
        "text": "Presents the accuracy of TB-LAMP as a replacement for smear microscopy, with the numbers of eligible and included participants by study and reference standard. Forest plots and pooled sensitivity and specificity estimates are given for each of the three culture-based standards. Table notes define the standards used.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "smear microscopy",
          "heading": true
        },
        {
          "term": "tb-lamp",
          "heading": true
        },
        {
          "term": "tb-lamp ranged",
          "heading": false
        },
        {
          "term": "rfa",
          "heading": false
        },
        {
          "term": "replacement test",
          "heading": true
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "studies ranged",
          "heading": false
        },
        {
          "term": "pooled specificity",
          "heading": false
        }
      ],
      "extract": "Of the 4 760 adults eligible for inclusion in the analysis, 1 810 participants (38%) across 7 studies qualified for Standard 1 status; 3 110 participants (65%) across 10 studies qualified for Standard 2; and 4 596 participants (97%) across 13 qualified for Standard 3 (Table 3). Table 3. TB-LAMP as a replacement test for smear microscopy: eligible and included patients, by reference standard and study site (see Annex",
      "extractCut": true
    },
    {
      "id": "sec-014-52-accuracy-of-tb-lamp-as-a-replacement-test-for",
      "number": "5.2",
      "title": "Accuracy of TB-LAMP as a replacement test for smear microscopy in persons living with HIV",
      "level": 2,
      "pageStart": 31,
      "pageEnd": 32,
      "labelStart": "19",
      "labelEnd": "20",
      "words": 483,
      "summary": {
        "text": "Reports the limited data on TB-LAMP accuracy among adults living with HIV, giving the ranges of sensitivity and specificity across studies for each reference standard. It notes greater heterogeneity and provides pooled estimates in a table.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tb-lamp",
          "heading": true
        },
        {
          "term": "pooled sensitivity",
          "heading": false
        },
        {
          "term": "studies qualified",
          "heading": false
        },
        {
          "term": "forest plots",
          "heading": false
        },
        {
          "term": "hiv",
          "heading": true
        },
        {
          "term": "hiv status",
          "heading": false
        },
        {
          "term": "individual studies",
          "heading": false
        },
        {
          "term": "across studies",
          "heading": false
        }
      ],
      "extract": "with HIV Most studies did not collect data on HIV status and most patients had unknown HIV status at the time of enrolment. Of the 385 adults with known HIV infection who were eligible for inclusion in the analysis, 169 participants (44%) in 2 studies qualified for Standard 1 status; 271 (70%) across 4 studies qualified for Standard 2; and 370 (96%) across 5 studies qualified for Standard 3. For Standard 1, the",
      "extractCut": true
    },
    {
      "id": "sec-015-53-accuracy-of-tb-lamp-as-an-add-on-test-followi",
      "number": "5.3",
      "title": "Accuracy of TB-LAMP as an add-on test following smear microscopy for smear-negative adults",
      "level": 2,
      "pageStart": 32,
      "pageEnd": 34,
      "labelStart": "20",
      "labelEnd": "22",
      "words": 823,
      "summary": {
        "text": "Presents the accuracy of TB-LAMP as an add-on test for adults with two negative smear results, with participant numbers by study and reference standard. Pooled sensitivity and specificity for smear-negative, culture-positive TB are shown with forest plots. Table notes define the culture standards.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "add-on test",
          "heading": true
        },
        {
          "term": "tb-lamp",
          "heading": true
        },
        {
          "term": "rfa",
          "heading": false
        },
        {
          "term": "sputum-smear microscopy",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "smear-negative",
          "heading": true
        },
        {
          "term": "eval",
          "heading": false
        },
        {
          "term": "smear-negative culture-positive",
          "heading": false
        }
      ],
      "extract": "adults The diagnostic accuracy of TB-LAMP for detecting smear-negative culture-confirmed pulmonary TB was limited to adult participants with two negative sputum-smear microscopy results. Of 2 972 participants eligible for the analysis, 1 349 (45%) across 7 studies qualified for Standard 1 status; 2 190 (74%) across 9 studies qualified for Standard 2; and 2 916 (98%) across 11 studies qualified for Standard 3 (Table",
      "extractCut": true
    },
    {
      "id": "sec-016-54-accuracy-of-tb-lamp-compared-with-xpert-mtbri",
      "number": "5.4",
      "title": "Accuracy of TB-LAMP compared with Xpert MTB/RIF assay for detecting pulmonary TB",
      "level": 2,
      "pageStart": 34,
      "pageEnd": 36,
      "labelStart": "22",
      "labelEnd": "24",
      "words": 640,
      "summary": {
        "text": "Compares the diagnostic accuracy of TB-LAMP and the Xpert MTB/RIF assay in participants tested with both, giving numbers of included participants by study. Pooled sensitivity and specificity for each test and their differences are presented across three reference standards.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mtb rif",
          "heading": true
        },
        {
          "term": "xpert mtb",
          "heading": true
        },
        {
          "term": "rif assay",
          "heading": true
        },
        {
          "term": "tb-lamp",
          "heading": true
        },
        {
          "term": "rfa",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        },
        {
          "term": "both tb-lamp",
          "heading": false
        },
        {
          "term": "sputum specimens",
          "heading": false
        }
      ],
      "extract": "The difference in diagnostic accuracy between TB-LAMP and the Xpert MTB/RIF assay for detecting pulmonary TB compared with culture as the reference standard was determined for participants who underwent both TB-LAMP and Xpert MTB/RIF testing on non-frozen specimens. Of 2 837 participants eligible for inclusion in the analysis, 1 075 (38%) across four studies qualified for Standard 1 status; 1 809 (64%) across 6",
      "extractCut": true
    },
    {
      "id": "sec-017-tb-lamp-is-used-to-detect-pulmonary-tb-among-all",
      "number": null,
      "title": "TB-LAMP is used to detect pulmonary TB among all adults and among HIV-positive adults",
      "level": 1,
      "pageStart": 36,
      "pageEnd": 37,
      "labelStart": "24",
      "labelEnd": "25",
      "words": 103,
      "summary": {
        "text": "Reports that indeterminate or invalid TB-LAMP results were rare, with a pooled proportion of about zero among all adults and among those with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv-positive adults",
          "heading": true
        },
        {
          "term": "tb-lamp",
          "heading": true
        },
        {
          "term": "among hiv-positive",
          "heading": true
        }
      ],
      "extract": "to detect pulmonary TB among all adults and among HIV-positive adults All 4 760 patients eligible for the analysis of the accuracy of TB-LAMP among adults were included in the analysis to determine the proportion of indeterminate or invalid TB-LAMP results (Table 3). The proportion of indeterminate TB-LAMP results was 0% in 11 studies and 1% in 2 studies. There was minimal heterogeneity across studies (I2: 28%; P =",
      "extractCut": true
    },
    {
      "id": "sec-018-6-cost-effectiveness-analysis",
      "number": "6",
      "title": "Cost-effectiveness analysis",
      "level": 1,
      "pageStart": 37,
      "pageEnd": 38,
      "labelStart": "25",
      "labelEnd": "26",
      "words": 476,
      "summary": {
        "text": "Summarizes a costing study of TB-LAMP and Xpert MTB/RIF in peripheral laboratories in Malawi and Viet Nam, comparing TB-LAMP strategies with microscopy-based care. It gives per-test costs and affordability and cost-effectiveness findings, and cautions policy-makers to weigh feasibility and costs before adoption.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tb-lamp assay",
          "heading": false
        },
        {
          "term": "sputum-smear microscopy",
          "heading": false
        },
        {
          "term": "viet nam",
          "heading": false
        },
        {
          "term": "smear microscopy",
          "heading": false
        },
        {
          "term": "rif assay",
          "heading": false
        },
        {
          "term": "peripheral laboratories",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        }
      ],
      "extract": "6. Cost-effectiveness analysis This analysis provides evidence for the cost–effectiveness of TB-LAMP as a replacement test for sputum-smear microscopy or as an add-on test to sputum-smear microscopy in the further testing of smear-negative patients compared with the standard of care in settings where coverage of the Xpert MTB/RIF assay is limited (H. Sohn, Cost, affordability, and cost-effectiveness of TB-LAMP",
      "extractCut": true
    },
    {
      "id": "sec-019-7-summary-from-evidence-to-recommendations",
      "number": "7",
      "title": "Summary: from evidence to recommendations",
      "level": 1,
      "pageStart": 38,
      "pageEnd": 38,
      "labelStart": "26",
      "labelEnd": "26",
      "words": 41,
      "summary": {
        "text": "Introduces the evidence-to-recommendation summary, noting that TB-LAMP accuracy on sputum was determined from 13 studies in intermediate- and high-burden countries.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "burdens",
          "heading": false
        },
        {
          "term": "intermediate",
          "heading": false
        },
        {
          "term": "tb-lamp",
          "heading": false
        }
      ],
      "extract": "The accuracy of TB-LAMP performed directly on sputum samples for diagnosing pulmonary TB among adults who have not received TB treatment within 60 days of enrolment was determined from 13 studies performed in countries with intermediate and high burdens of TB.",
      "extractCut": false
    },
    {
      "id": "sec-020-71-tb-lamp-for-the-detection-of-pulmonary-tb-in",
      "number": "7.1",
      "title": "TB-LAMP for the detection of pulmonary TB in all adults",
      "level": 2,
      "pageStart": 38,
      "pageEnd": 38,
      "labelStart": "26",
      "labelEnd": "26",
      "words": 423,
      "summary": {
        "text": "Explains the Guideline Development Group's reasoning on TB-LAMP for all adults: higher sensitivity than microscopy with slightly lower specificity, partly attributed to culture misclassification. It weighs the extra cases detected per 1 000 tested against false positives and concludes the trade-off is acceptable.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tb-lamp",
          "heading": true
        },
        {
          "term": "pre-test probability",
          "heading": false
        },
        {
          "term": "cases misclassified",
          "heading": false
        },
        {
          "term": "sputum-smear microscopy",
          "heading": false
        },
        {
          "term": "smear microscopy",
          "heading": false
        },
        {
          "term": "individuals tested",
          "heading": false
        },
        {
          "term": "gdg felt",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "Using data from the 1 810 persons with signs and symptoms consistent with TB for whom the most stringent reference standard could be used (Standard 1), TB-LAMP had a pooled sensitivity that was 15% higher than smear microscopy (78% compared with 63%). Although pooled specificity estimates for TB-LAMP were 2% lower (98% compared with 100%), this may be partly explained by the identification of TB cases who were",
      "extractCut": true
    },
    {
      "id": "sec-021-72-tb-lamp-for-the-detection-of-pulmonary-tb-in",
      "number": "7.2",
      "title": "TB-LAMP for the detection of pulmonary TB in adults living with HIV",
      "level": 2,
      "pageStart": 38,
      "pageEnd": 39,
      "labelStart": "26",
      "labelEnd": "27",
      "words": 206,
      "summary": {
        "text": "Reports that in a small HIV-positive group TB-LAMP performed about the same as smear microscopy, and explains why the group made no specific recommendation for people living with HIV, citing limited evidence.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tb-lamp",
          "heading": true
        },
        {
          "term": "sputum-smear microscopy",
          "heading": false
        },
        {
          "term": "smear microscopy",
          "heading": false
        },
        {
          "term": "hiv-positive adults",
          "heading": false
        },
        {
          "term": "pulmonary",
          "heading": true
        },
        {
          "term": "gdg",
          "heading": false
        }
      ],
      "extract": "Data from 4 studies (271 participants) that included HIV-positive adults with signs and symptoms consistent with pulmonary TB and that evaluated the accuracy of TB-LAMP demonstrated sensitivity and specificity similar to sputum-smear microscopy (sensitivity: 64% for TB-LAMP and 62% for smear microscopy; specificity: 99% for TB-LAMP and 99% for smear microscopy)(Annex 2, Table 11). Based on this limited dataset,",
      "extractCut": true
    },
    {
      "id": "sec-022-73-tb-lamp-as-an-add-on-test-for-detecting-of-pu",
      "number": "7.3",
      "title": "TB-LAMP as an add-on test for detecting of pulmonary TB in adults following negative smear microscopy",
      "level": 2,
      "pageStart": 39,
      "pageEnd": 39,
      "labelStart": "27",
      "labelEnd": "27",
      "words": 391,
      "summary": {
        "text": "Sets out the reasoning for TB-LAMP as an add-on test after negative smear microscopy, citing a 42% incremental yield and slightly lower specificity. It concludes that more cases would be found with an acceptable number of false positives.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "smear microscopy",
          "heading": true
        },
        {
          "term": "tb-lamp",
          "heading": true
        },
        {
          "term": "pre-test probability",
          "heading": false
        },
        {
          "term": "sputum-smear microscopy",
          "heading": false
        },
        {
          "term": "incorrect identification",
          "heading": false
        },
        {
          "term": "individuals tested",
          "heading": false
        },
        {
          "term": "gdg felt",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "smear microscopy Using data from the 1 349 persons with signs and symptoms consistent with TB in the 7 studies to which the most stringent reference standard could be applied (Standard 1), TB-LAMP showed a 42% incremental yield in patients with culture-confirmed TB who had a negative sputum-smear microscopy result. Pooled specificity estimates for TB-LAMP were 2% lower (98% versus 100% for smear microscopy), and",
      "extractCut": true
    },
    {
      "id": "sec-023-74-tb-lamp-as-a-replacement-test-for-the-xpert-m",
      "number": "7.4",
      "title": "TB-LAMP as a replacement test for the Xpert MTB/RIF assay for detecting pulmonary TB in adults",
      "level": 2,
      "pageStart": 39,
      "pageEnd": 41,
      "labelStart": "27",
      "labelEnd": "29",
      "words": 257,
      "summary": {
        "text": "Compares TB-LAMP with Xpert MTB/RIF, noting lower sensitivity and no rifampicin resistance detection, and explains why Xpert remains preferred where resources allow while TB-LAMP may suit peripheral sites.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rif assay",
          "heading": true
        },
        {
          "term": "mtb rif",
          "heading": true
        },
        {
          "term": "xpert mtb",
          "heading": true
        },
        {
          "term": "tb-lamp",
          "heading": true
        },
        {
          "term": "rifampicin resistance",
          "heading": false
        },
        {
          "term": "adults",
          "heading": true
        },
        {
          "term": "replacement",
          "heading": true
        },
        {
          "term": "microscopy",
          "heading": false
        }
      ],
      "extract": "TB in adults Although better than microscopy, the pooled sensitivity of TB-LAMP is lower than what has been reported for the Xpert MTB/RIF assay (89%; 95% credible interval: 85–92).11 The specificity of all three tests is similar. In head-to-head comparisons, TB-LAMP appeared to be less sensitive than the Xpert MTB/RIF assay, but the difference in sensitivity was not statistically significant except when using the",
      "extractCut": true
    },
    {
      "id": "sec-024-8-who-policy-recommendations",
      "number": "8",
      "title": "WHO policy recommendations",
      "level": 1,
      "pageStart": 41,
      "pageEnd": 42,
      "labelStart": "29",
      "labelEnd": "30",
      "words": 219,
      "summary": {
        "text": "States WHO's two conditional recommendations, based on very low-quality evidence, for TB-LAMP as a replacement for or follow-on to smear microscopy in symptomatic adults. Remarks restrict their use to sputum, caution against replacing rapid rifampicin-resistance tests and note uncertainty for people with HIV and extrapolation to children.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "sputum-smear microscopy",
          "heading": false
        },
        {
          "term": "symptoms consistent",
          "heading": false
        },
        {
          "term": "low-quality evidence",
          "heading": false
        },
        {
          "term": "sputum specimens",
          "heading": false
        },
        {
          "term": "tb-lamp",
          "heading": false
        },
        {
          "term": "conditional recommendation",
          "heading": false
        },
        {
          "term": "signs",
          "heading": false
        }
      ],
      "extract": "8. WHO policy recommendations Given the GRADE evidence assessment and considering the relative benefits and harms associated with the use of the TB-LAMP, WHO recommends the following. 1. \u0007TB-LAMP may be used as a replacement test for sputum-smear microscopy to diagnose pulmonary TB in adults with signs and symptoms consistent with TB (conditional recommendation, very low-quality evidence). 2. \u0007TB-LAMP may be used as",
      "extractCut": true
    },
    {
      "id": "sec-025-9-implementation-considerations",
      "number": "9",
      "title": "Implementation considerations",
      "level": 1,
      "pageStart": 42,
      "pageEnd": 43,
      "labelStart": "30",
      "labelEnd": "31",
      "words": 252,
      "summary": {
        "text": "Lists implementation considerations for TB-LAMP, including electricity, storage temperature, waste disposal and stock needs. It also notes that smear microscopy is still needed for treatment monitoring and that Xpert MTB/RIF should not be replaced.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "sputum microscopy",
          "heading": false
        },
        {
          "term": "smear microscopy",
          "heading": false
        },
        {
          "term": "rif assay",
          "heading": false
        },
        {
          "term": "mtb rif",
          "heading": false
        },
        {
          "term": "tb-lamp",
          "heading": false
        },
        {
          "term": "xpert mtb",
          "heading": false
        },
        {
          "term": "conventional sputum",
          "heading": false
        },
        {
          "term": "temperatures",
          "heading": false
        }
      ],
      "extract": "9. Implementation considerations The systematic review supports the use of TB-LAMP as a replacement test for smear microscopy for diagnosing pulmonary TB in countries with an intermediate or high burden of TB. However, the Xpert MTB/RIF assay should remain the preferred diagnostic for all persons suspected of having TB, providing there are sufficient resources and infrastructure to support its use, given the",
      "extractCut": true
    },
    {
      "id": "sec-026-10-plans-for-disseminating-whos-guidance-on-tb-l",
      "number": "10",
      "title": "Plans for disseminating WHO’s guidance on TB-LAMP",
      "level": 1,
      "pageStart": 43,
      "pageEnd": 44,
      "labelStart": "31",
      "labelEnd": "32",
      "words": 56,
      "summary": {
        "text": "Describes how the TB-LAMP guidance will be published online and distributed to WHO offices, Member States and partner networks.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "disseminating",
          "heading": true
        },
        {
          "term": "tb-lamp",
          "heading": true
        },
        {
          "term": "guidance",
          "heading": true
        }
      ],
      "extract": "10. Plans for disseminating WHO’s guidance on TB-LAMP This WHO guidance will be published online (http://www.who.int/tb/publications/lamp-diagnosis- molecular/en/) and disseminated through WHO’s Global TB Department listserv to all WHO Regional and Country Offices and Member States, the Global Laboratory Initiative, the New Diagnostics Working Group of the Stop TB Partnership, and donors, technical agencies and",
      "extractCut": true
    },
    {
      "id": "sec-027-11-research-needs",
      "number": "11",
      "title": "Research needs",
      "level": 1,
      "pageStart": 44,
      "pageEnd": 45,
      "labelStart": "32",
      "labelEnd": "33",
      "words": 185,
      "summary": {
        "text": "Lists research needs for TB-LAMP, such as studies with stronger culture reference standards, evaluation of diagnostic algorithms, training needs, patient impact and country-specific cost analyses.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "research",
          "heading": true
        },
        {
          "term": "tb-lamp",
          "heading": false
        },
        {
          "term": "assay",
          "heading": false
        },
        {
          "term": "studies",
          "heading": false
        },
        {
          "term": "culture",
          "heading": false
        },
        {
          "term": "standards",
          "heading": false
        }
      ],
      "extract": "11. Research needs The current recommendations for the commercial TB-LAMP manual assay should not prevent or restrict further research on new TB diagnostics, especially point-of-care assays that can be used as close as possible to where patients access TB treatment. Additional studies using standardized protocols that include a high-quality culture reference standard (liquid culture results on at least two samples)",
      "extractCut": true
    },
    {
      "id": "sec-028-12-annexes",
      "number": "12",
      "title": "Annexes",
      "level": 1,
      "pageStart": 45,
      "pageEnd": 45,
      "labelStart": "33",
      "labelEnd": "33",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-029-annex-1-references-to-studies-for-the-systematic",
      "number": "Annex 1",
      "title": "References to studies for the systematic review of the diagnostic accuracy of TB-LAMP",
      "level": 1,
      "pageStart": 45,
      "pageEnd": 47,
      "labelStart": "33",
      "labelEnd": "35",
      "words": 528,
      "summary": {
        "text": "A reference list of the studies included in, and excluded from, the systematic review of TB-LAMP diagnostic accuracy, many unpublished or submitted for publication.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lamp request",
          "heading": false
        },
        {
          "term": "applications memorandum",
          "heading": false
        },
        {
          "term": "find lamp",
          "heading": false
        },
        {
          "term": "tb-lamp",
          "heading": true
        },
        {
          "term": "pulmonary tuberculosis",
          "heading": false
        },
        {
          "term": "multi-centre study",
          "heading": false
        },
        {
          "term": "loop-mediated isothermal",
          "heading": false
        },
        {
          "term": "isothermal amplification",
          "heading": false
        }
      ],
      "extract": "TB-LAMP Studies included in the review 1. \u0007Hang PT, Peter J, Mello FCQ, Parraga T, Nguyen TNL, Nabeta P, et al. Performance of the TB-LAMP diagnostic assay in reference laboratories – results from a multi-centre study (Brazil, Peru, South Africa, Vietnam). Submitted to the International Journal of Tuberculosis and Lung Disease, April 2016. 2. \u0007Gray CM, Katamba A, Narang P, Giraldo J, Zamudio C, Joloba M, et al.",
      "extractCut": true
    },
    {
      "id": "sec-030-annex-2-grade-evidence-profiles",
      "number": "Annex 2",
      "title": "GRADE Evidence Profiles",
      "level": 1,
      "pageStart": 47,
      "pageEnd": 50,
      "labelStart": "35",
      "labelEnd": "38",
      "words": 1477,
      "summary": {
        "text": "Presents GRADE evidence profiles comparing TB-LAMP with sputum-smear microscopy for diagnosing pulmonary TB in adults, against a culture reference standard. Tables give pooled sensitivity and specificity and the expected true and false positives and negatives per 1000 patients at different pre-test probabilities. Footnotes explain why the evidence was rated very low or low quality, citing risk of bias, indirectness and heterogeneity across studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "madagascar rfa",
          "heading": false
        },
        {
          "term": "seriousa seriousb",
          "heading": false
        },
        {
          "term": "uganda rfa",
          "heading": false
        },
        {
          "term": "tb-lamp smear",
          "heading": false
        },
        {
          "term": "tb-lamp fewer",
          "heading": false
        },
        {
          "term": "grade evidence",
          "heading": true
        },
        {
          "term": "tanzania rfa",
          "heading": false
        },
        {
          "term": "smear microscopy",
          "heading": false
        }
      ],
      "extract": "Table 10. GRADE evidence profile: accuracy of TB-LAMP as a replacement test for sputum-smear microscopy for diagnosing pulmonary TB among all adults suspected of having pulmonary TB Question: What is the diagnostic accuracy of TB-LAMP for to diagnose pulmonary tuberculosis in all adults with presumptive pulmonary TB compared with a culture reference standard? Participants: Adult patients suspected of having TB Prior",
      "extractCut": true
    },
    {
      "id": "sec-031-annex-3-abstracts-for-unpublished-studies",
      "number": "Annex 3",
      "title": "Abstracts for unpublished studies",
      "level": 1,
      "pageStart": 50,
      "pageEnd": 52,
      "labelStart": "38",
      "labelEnd": "40",
      "words": 1258,
      "summary": {
        "text": "Reproduces abstracts of unpublished studies on TB-LAMP included in the review, beginning with a Côte d'Ivoire study comparing smear microscopy, TB-LAMP and GeneXpert MTB/RIF against liquid culture in symptomatic patients. Each abstract outlines background, methods, sample sizes and the sensitivity and specificity results obtained. The section ends with WHO Global TB Programme contact details.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "smear microscopy",
          "heading": false
        },
        {
          "term": "loopamp mtbc",
          "heading": false
        },
        {
          "term": "single tb-lamp",
          "heading": false
        },
        {
          "term": "ziehl neelsen",
          "heading": false
        },
        {
          "term": "loopamp assay",
          "heading": false
        },
        {
          "term": "tb-lamp test",
          "heading": false
        },
        {
          "term": "eiken loopamp",
          "heading": false
        },
        {
          "term": "ung hoa",
          "heading": false
        }
      ],
      "extract": "Included study 4. Comparison of pulmonary tuberculosis diagnosis by AFB detection, TB-LAMP and GeneXpert MTB/RIF in Ivory Coast K. N’guessan,1 K. Horo2, I. Coulibaly,3 J. Adegbele,1 N. Kouame-Adjei,3 H. Seck-Angu,1 A. Guei,1 J. Kouakou,4 M. Dosso1 1 Laboratoire Nationale de Référence de la Tuberculose, Institut Pasteur de Côte d’Ivoire, 01BP 490 Abidjan 01 2 Service de Pneumologie CHU de Cocody 3 Centre",
      "extractCut": true
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 1,
        "items": [
          "GRADE Evidence Profiles"
        ]
      },
      "found_not_listed": {
        "count": 1,
        "items": [
          "7 Studies excluded"
        ]
      },
      "page_mismatch": {
        "count": 0,
        "items": []
      }
    },
    "figureSequenceGaps": [],
    "pageLabelConflicts": {
      "count": 0,
      "items": []
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "tb-lamp smear",
      "heading": true
    },
    {
      "term": "tb-lamp studies",
      "heading": true
    },
    {
      "term": "tb-lamp assay",
      "heading": true
    },
    {
      "term": "tb-lamp specificity",
      "heading": true
    },
    {
      "term": "tb-lamp sensitivity",
      "heading": true
    },
    {
      "term": "tb-lamp test",
      "heading": true
    },
    {
      "term": "indeterminate tb-lamp",
      "heading": false
    },
    {
      "term": "tb-lamp performed",
      "heading": false
    },
    {
      "term": "tb-lamp compared",
      "heading": true
    },
    {
      "term": "tb-lamp among",
      "heading": true
    },
    {
      "term": "tb-lamp testing",
      "heading": false
    },
    {
      "term": "tb-lamp ranged",
      "heading": false
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": "i",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 2,
      "label": "ii",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "iii",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "iv",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 5,
      "label": "v",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 6,
      "label": "vi",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 7,
      "label": "vii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 8,
      "label": "viii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 9,
      "label": "ix",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 10,
      "label": "x",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 11,
      "label": "xi",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 12,
      "label": "xii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 13,
      "label": "1",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 14,
      "label": "2",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 15,
      "label": "3",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 16,
      "label": "4",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 17,
      "label": "5",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 18,
      "label": "6",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 19,
      "label": "7",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 20,
      "label": "8",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 21,
      "label": "9",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 22,
      "label": "10",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 23,
      "label": "11",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 24,
      "label": "12",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 25,
      "label": "13",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 26,
      "label": "14",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 27,
      "label": "15",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 28,
      "label": "16",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 29,
      "label": "17",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 30,
      "label": "18",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 31,
      "label": "19",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 32,
      "label": "20",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 33,
      "label": "21",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 34,
      "label": "22",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 35,
      "label": "23",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 36,
      "label": "24",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 37,
      "label": "25",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 38,
      "label": "26",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 39,
      "label": "27",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 40,
      "label": "28",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 41,
      "label": "29",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 42,
      "label": "30",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 43,
      "label": "31",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 44,
      "label": "32",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 45,
      "label": "33",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 46,
      "label": "34",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 47,
      "label": "35",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 48,
      "label": "36",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 49,
      "label": "37",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 50,
      "label": "38",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 51,
      "label": "39",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 52,
      "label": "40",
      "source": "pdf-labels",
      "confidence": 0.7
    }
  ],
  "figures": [
    {
      "kind": "figure",
      "number": "1",
      "title": "Molecular principles of TB-LAMP",
      "page": 16,
      "pageLabel": "4",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "2",
      "title": "Visual display of TB-LAMP results under ultraviolet light",
      "page": 17,
      "pageLabel": "5",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "3",
      "title": "Schematic description of the workflow for TB-LAMP",
      "page": 18,
      "pageLabel": "6",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "4",
      "title": "Flow diagram of the 20 TB-LAMP studies identified through a systematic",
      "page": 25,
      "pageLabel": "13",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "1",
      "title": "Characteristics for all studies included in the evaluation of TB-LAMP",
      "page": 26,
      "pageLabel": "14",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "2",
      "title": "Risk of bias and applicability concerns: review authors’ judgements about each",
      "page": 27,
      "pageLabel": "15",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "3",
      "title": "TB-LAMP as a replacement test for smear microscopy: eligible and included",
      "page": 29,
      "pageLabel": "17",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "5",
      "title": "Forest plots of TB-LAMP sensitivity and specificity for detecting TB compared",
      "page": 30,
      "pageLabel": "18",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "6",
      "title": "Forest plots of TB-LAMP sensitivity and specificity for detecting TB among",
      "page": 31,
      "pageLabel": "19",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "4",
      "title": "TB-LAMP as a replacement test for smear microscopy: estimates of pooled",
      "page": 31,
      "pageLabel": "19",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "5",
      "title": "TB-LAMP as a replacement test for smear microscopy in persons living with",
      "page": 32,
      "pageLabel": "20",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "6",
      "title": "TB-LAMP as an add-on test following negative sputum-smear microscopy:",
      "page": 32,
      "pageLabel": "20",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "7",
      "title": "Forest plots of TB-LAMP sensitivity and specificity for detecting TB among",
      "page": 33,
      "pageLabel": "21",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "7",
      "title": "TB-LAMP as an add-on test following smear microscopy: pooled sensitivity and",
      "page": 34,
      "pageLabel": "22",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "8",
      "title": "Diagnostic accuracy of TB-LAMP compared with the Xpert MTB/RIF assay:",
      "page": 35,
      "pageLabel": "23",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "9",
      "title": "Accuracy of TB-LAMP and the Xpert MTB/RIF assay: pooled sensitivity and",
      "page": 36,
      "pageLabel": "24",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    }
  ],
  "images": [
    {
      "id": "img-p016-1",
      "file": "images/img-p016-1.webp",
      "page": 16,
      "narratives": {
        "en": "Schematic diagram of the molecular principles of TB-LAMP (Figure 1): coloured DNA strands with primer-binding regions labelled F1, F2, F1c, F2c, B1, B2, B1c and B2c pass through numbered stages (8)–(11) linked by arrows in a cycle. Loop (dumbbell and hairpin) structures form at the strand ends and are elongated into long zigzag products made of alternately inverted repeats of the target sequence.",
        "ar": "مخطط يبيّن المبادئ الجزيئية لاختبار TB-LAMP (الشكل 1): خيوط ملوّنة من الدنا تحمل مناطق ارتباط البادئات الموسومة F1 وF2 وF1c وF2c وB1 وB2 وB1c وB2c، تمر بمراحل مرقّمة من (8) إلى (11) تربط بينها أسهم في دورة. وتتشكل بنى عروية (على هيئة دمبل ودبوس شعر) عند أطراف الخيوط ثم تستطيل إلى نواتج طويلة متعرجة مكوّنة من تكرارات مقلوبة بالتناوب للتسلسل المستهدف.",
        "zh": "TB-LAMP分子原理示意图（图1）：带有引物结合区（标注为F1、F2、F1c、F2c、B1、B2、B1c和B2c）的彩色DNA链经历编号为(8)至(11)的各阶段，各阶段以箭头连成循环。链末端形成环状（哑铃状和发夹状）结构，并延伸为由靶序列交替反向重复构成的长锯齿状产物。",
        "es": "Diagrama esquemático de los principios moleculares de la TB-LAMP (figura 1): hebras de ADN de colores con regiones de unión de cebadores marcadas F1, F2, F1c, F2c, B1, B2, B1c y B2c pasan por etapas numeradas (8)–(11) unidas por flechas en un ciclo. En los extremos de las hebras se forman estructuras en bucle (en mancuerna y en horquilla) que se alargan en productos largos en zigzag compuestos de repeticiones invertidas alternas de la secuencia diana.",
        "fr": "Schéma des principes moléculaires du TB-LAMP (figure 1) : des brins d'ADN colorés portant des régions de fixation des amorces marquées F1, F2, F1c, F2c, B1, B2, B1c et B2c passent par des étapes numérotées (8) à (11) reliées par des flèches en un cycle. Des structures en boucle (en haltère et en épingle à cheveux) se forment aux extrémités des brins et s'allongent en longs produits en zigzag constitués de répétitions inversées alternées de la séquence cible.",
        "ru": "Схема молекулярных принципов TB-LAMP (рисунок 1): цветные нити ДНК с участками связывания праймеров, обозначенными F1, F2, F1c, F2c, B1, B2, B1c и B2c, проходят пронумерованные этапы (8)–(11), соединенные стрелками в цикл. На концах нитей образуются петлевые структуры (в форме гантели и шпильки), которые удлиняются в длинные зигзагообразные продукты из чередующихся инвертированных повторов целевой последовательности."
      },
      "state": "draft"
    },
    {
      "id": "img-p017-1",
      "file": "images/img-p017-1.webp",
      "page": 17,
      "narratives": {
        "en": "Photograph of a strip of eight reaction tubes under ultraviolet light (Figure 2): the four tubes on the left are clear, while the four on the right show bright green fluorescence at the bottom, illustrating negative and positive TB-LAMP results.",
        "ar": "صورة فوتوغرافية لشريط من ثمانية أنابيب تفاعل تحت الأشعة فوق البنفسجية (الشكل 2): الأنابيب الأربعة على اليسار صافية، بينما تُظهر الأنابيب الأربعة على اليمين تألقاً أخضر ساطعاً في قاعها، مما يوضح النتائج السلبية والإيجابية لاختبار TB-LAMP.",
        "zh": "紫外光下一排八支反应管的照片（图2）：左侧四支管清澈，右侧四支管底部呈明亮的绿色荧光，示意TB-LAMP的阴性和阳性结果。",
        "es": "Fotografía de una tira de ocho tubos de reacción bajo luz ultravioleta (figura 2): los cuatro tubos de la izquierda son transparentes, mientras que los cuatro de la derecha muestran una fluorescencia verde brillante en el fondo, lo que ilustra resultados negativos y positivos de la TB-LAMP.",
        "fr": "Photographie d'une barrette de huit tubes réactionnels sous lumière ultraviolette (figure 2) : les quatre tubes de gauche sont limpides, tandis que les quatre de droite présentent une fluorescence vert vif au fond, illustrant des résultats négatifs et positifs du TB-LAMP.",
        "ru": "Фотография полоски из восьми реакционных пробирок в ультрафиолетовом свете (рисунок 2): четыре пробирки слева прозрачны, а четыре справа ярко флуоресцируют зеленым у дна, что иллюстрирует отрицательные и положительные результаты TB-LAMP."
      },
      "state": "draft"
    },
    {
      "id": "img-p018-1",
      "file": "images/img-p018-1.webp",
      "page": 18,
      "narratives": {
        "en": "Workflow diagram of TB-LAMP made of photographs joined by arrows (Figure 3). Steps: collect 60 µl from the sputum cup using an Eiken disposable pipette into a heating tube; heat on a heating block at 90 °C for 5 min; attach and shake the adsorbent tube; fit the injection cap; add 30–35 µl (between lines) to reaction tubes containing dried reagents; close lids and let stand upside down for 2 min; mix; run the LAMP reaction at 67 °C for 40 min; and detect the fluorescent signal.",
        "ar": "مخطط لسير عمل اختبار TB-LAMP مكوّن من صور فوتوغرافية تربط بينها أسهم (الشكل 3). الخطوات: جمع 60 ميكرولتراً من كوب البلغم باستخدام ماصة Eiken أحادية الاستعمال ونقلها إلى أنبوب التسخين؛ التسخين على كتلة تسخين عند 90 درجة مئوية لمدة 5 دقائق؛ تركيب الأنبوب الماص ورجّه؛ تركيب غطاء الحقن؛ إضافة 30–35 ميكرولتراً (بين الخطين) إلى أنابيب التفاعل التي تحتوي على كواشف مجففة؛ إغلاق الأغطية وتركها مقلوبة لمدة دقيقتين؛ الخلط؛ إجراء تفاعل LAMP عند 67 درجة مئوية لمدة 40 دقيقة؛ ثم الكشف عن إشارة التألق.",
        "zh": "由照片和箭头组成的TB-LAMP工作流程图（图3）。步骤：用Eiken一次性吸管从痰杯中吸取60 µl转入加热管；在加热块上90 °C加热5分钟；连接吸附管并摇匀；装上注射帽；向含干燥试剂的反应管中加入30–35 µl（两条刻线之间）；盖上管盖并倒置静置2分钟；混匀；在67 °C下进行LAMP反应40分钟；检测荧光信号。",
        "es": "Diagrama del flujo de trabajo de la TB-LAMP compuesto por fotografías unidas por flechas (figura 3). Pasos: recoger 60 µl del recipiente de esputo con una pipeta desechable Eiken y pasarlos al tubo de calentamiento; calentar en un bloque térmico a 90 °C durante 5 min; acoplar y agitar el tubo adsorbente; colocar el tapón de inyección; añadir 30–35 µl (entre las líneas) a los tubos de reacción con reactivos desecados; cerrar las tapas y dejar invertidos durante 2 min; mezclar; realizar la reacción LAMP a 67 °C durante 40 min, y detectar la señal fluorescente.",
        "fr": "Schéma du déroulement du TB-LAMP composé de photographies reliées par des flèches (figure 3). Étapes : prélever 60 µl dans le pot à crachats à l'aide d'une pipette jetable Eiken et les transférer dans le tube de chauffage ; chauffer sur un bloc chauffant à 90 °C pendant 5 min ; fixer et agiter le tube adsorbant ; poser le capuchon d'injection ; ajouter 30–35 µl (entre les traits) dans les tubes réactionnels contenant les réactifs séchés ; fermer les bouchons et laisser reposer à l'envers pendant 2 min ; mélanger ; effectuer la réaction LAMP à 67 °C pendant 40 min ; détecter le signal fluorescent.",
        "ru": "Схема рабочего процесса TB-LAMP из фотографий, соединенных стрелками (рисунок 3). Этапы: отобрать 60 мкл из контейнера с мокротой одноразовой пипеткой Eiken в нагревательную пробирку; нагреть в термоблоке при 90 °C в течение 5 мин; присоединить адсорбирующую пробирку и встряхнуть; надеть инъекционный колпачок; внести 30–35 мкл (между метками) в реакционные пробирки с высушенными реагентами; закрыть крышки и оставить перевернутыми на 2 мин; перемешать; провести реакцию LAMP при 67 °C в течение 40 мин; выявить флуоресцентный сигнал."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p025",
      "file": "figures/vfig-p025.webp",
      "page": 25,
      "shows": [
        "Figure 4"
      ],
      "narratives": {
        "en": "Flow diagram of TB-LAMP studies (Figure 4): 20 studies identified; 7 excluded (in 6, patients treated for TB within 60 days of enrolment were not excluded; in 1, MTBC speciation was not performed); 13 studies included. These comprise 4 evaluation studies (Brazil, Peru, South Africa, Viet Nam), 1 demonstration study (India), 7 RFA studies (Côte d'Ivoire, India, Madagascar, Malawi, Uganda, United Republic of Tanzania, Viet Nam) and 1 unpublished study (Haiti).",
        "ar": "مخطط انسيابي لدراسات اختبار TB-LAMP (الشكل 4): حُدِّدت 20 دراسة؛ واستُبعدت 7 دراسات (في 6 منها لم يُستبعد المرضى الذين عولجوا من السل في غضون 60 يوماً من التسجيل؛ وفي دراسة واحدة لم يُجرَ تحديد نوع معقّد المتفطرة السلية)؛ وأُدرجت 13 دراسة. وتضم هذه 4 دراسات تقييم (البرازيل وبيرو وجنوب أفريقيا وفييت نام)، ودراسة إيضاحية واحدة (الهند)، و7 دراسات طلب تقديم (كوت ديفوار والهند ومدغشقر وملاوي وأوغندا وجمهورية تنزانيا المتحدة وفييت نام)، ودراسة واحدة غير منشورة (هايتي).",
        "zh": "TB-LAMP研究流程图（图4）：共识别20项研究；排除7项（其中6项未排除入组前60天内接受过结核病治疗的患者；1项未进行结核分枝杆菌复合群菌种鉴定）；纳入13项研究。包括4项评估研究（巴西、秘鲁、南非、越南）、1项示范研究（印度）、7项RFA研究（科特迪瓦、印度、马达加斯加、马拉维、乌干达、坦桑尼亚联合共和国、越南）和1项未发表研究（海地）。",
        "es": "Diagrama de flujo de los estudios sobre la TB-LAMP (figura 4): se identificaron 20 estudios; se excluyeron 7 (en 6 no se excluyó a los pacientes tratados contra la tuberculosis en los 60 días previos a la inclusión; en 1 no se realizó la identificación de especie del CMTB), y se incluyeron 13. Estos comprenden 4 estudios de evaluación (Brasil, Perú, Sudáfrica, Viet Nam), 1 estudio de demostración (India), 7 estudios RFA (Côte d'Ivoire, India, Madagascar, Malawi, Uganda, República Unida de Tanzanía, Viet Nam) y 1 estudio no publicado (Haití).",
        "fr": "Diagramme de flux des études sur le TB-LAMP (figure 4) : 20 études identifiées ; 7 exclues (dans 6, les patients traités pour la tuberculose dans les 60 jours précédant l'inclusion n'avaient pas été exclus ; dans 1, l'identification de l'espèce du complexe M. tuberculosis n'avait pas été réalisée) ; 13 études incluses. Celles-ci comprennent 4 études d'évaluation (Brésil, Pérou, Afrique du Sud, Viet Nam), 1 étude de démonstration (Inde), 7 études RFA (Côte d'Ivoire, Inde, Madagascar, Malawi, Ouganda, République-Unie de Tanzanie, Viet Nam) et 1 étude non publiée (Haïti).",
        "ru": "Блок-схема исследований TB-LAMP (рисунок 4): выявлено 20 исследований; исключено 7 (в 6 не были исключены пациенты, получавшие лечение от ТБ в течение 60 дней до включения; в 1 не проводилась видовая идентификация МТБК); включено 13 исследований. Среди них 4 оценочных исследования (Бразилия, Перу, Южная Африка, Вьетнам), 1 демонстрационное (Индия), 7 исследований RFA (Кот-д'Ивуар, Индия, Мадагаскар, Малави, Уганда, Объединенная Республика Танзания, Вьетнам) и 1 неопубликованное (Гаити)."
      },
      "state": "draft"
    },
    {
      "id": "img-p030-1",
      "file": "images/img-p030-1.webp",
      "page": 30,
      "narratives": {
        "en": "Forest plot of TB-LAMP sensitivity and specificity with 95% confidence intervals for detecting TB against culture reference Standard 1 (Figure 5), with TP, FP, FN and TN counts for seven studies (Brazil, Peru, South Africa and Vietnam evaluation studies; Uganda and Madagascar RFA; Haiti unpublished). Sensitivity ranges from 0.66 (Uganda) to 0.91 (Peru), while specificity is 0.90–0.99.",
        "ar": "مخطط غابي لحساسية اختبار TB-LAMP ونوعيته مع فترات ثقة 95% للكشف عن السل مقارنةً بمعيار الزرع المرجعي 1 (الشكل 5)، مع أعداد النتائج الإيجابية الحقيقية والإيجابية الكاذبة والسلبية الكاذبة والسلبية الحقيقية لسبع دراسات (دراسات التقييم في البرازيل وبيرو وجنوب أفريقيا وفييت نام؛ ودراستا طلب التقديم في أوغندا ومدغشقر؛ ودراسة غير منشورة في هايتي). وتتراوح الحساسية بين 0.66 (أوغندا) و0.91 (بيرو)، بينما تبلغ النوعية 0.90–0.99.",
        "zh": "TB-LAMP检测结核病的敏感性和特异性（含95%置信区间）森林图，以培养参考标准1为对照（图5），列出七项研究的TP、FP、FN和TN计数（巴西、秘鲁、南非和越南评估研究；乌干达和马达加斯加RFA研究；海地未发表研究）。敏感性从0.66（乌干达）到0.91（秘鲁）不等，特异性为0.90–0.99。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad de la TB-LAMP, con intervalos de confianza del 95%, para detectar la tuberculosis frente al patrón de referencia de cultivo 1 (figura 5), con los recuentos de VP, FP, FN y VN de siete estudios (estudios de evaluación del Brasil, el Perú, Sudáfrica y Viet Nam; RFA de Uganda y Madagascar; estudio no publicado de Haití). La sensibilidad varía de 0,66 (Uganda) a 0,91 (Perú), y la especificidad es de 0,90–0,99.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité du TB-LAMP, avec intervalles de confiance à 95 %, pour la détection de la tuberculose par rapport à la norme de référence par culture 1 (figure 5), avec le nombre de VP, FP, FN et VN pour sept études (études d'évaluation au Brésil, au Pérou, en Afrique du Sud et au Viet Nam ; RFA en Ouganda et à Madagascar ; étude non publiée en Haïti). La sensibilité va de 0,66 (Ouganda) à 0,91 (Pérou), et la spécificité est de 0,90–0,99.",
        "ru": "Лесовидный график чувствительности и специфичности TB-LAMP с 95% доверительными интервалами для выявления ТБ по сравнению с культуральным эталонным стандартом 1 (рисунок 5) с числом ИП, ЛП, ЛО и ИО для семи исследований (оценочные исследования в Бразилии, Перу, Южной Африке и Вьетнаме; исследования RFA в Уганде и на Мадагаскаре; неопубликованное исследование на Гаити). Чувствительность колеблется от 0,66 (Уганда) до 0,91 (Перу), а специфичность составляет 0,90–0,99."
      },
      "state": "draft"
    },
    {
      "id": "img-p030-2",
      "file": "images/img-p030-2.webp",
      "page": 30,
      "narratives": {
        "en": "Forest plot of TB-LAMP sensitivity and specificity with 95% confidence intervals against culture reference Standard 2 (Figure 5), with TP, FP, FN and TN counts for ten studies, adding India (Demo), Malawi (RFA) and Tanzania (RFA) to those in Standard 1. Sensitivity ranges from 0.62 (Malawi) to 0.91 (Peru), while specificity is 0.90–1.00.",
        "ar": "مخطط غابي لحساسية اختبار TB-LAMP ونوعيته مع فترات ثقة 95% مقارنةً بمعيار الزرع المرجعي 2 (الشكل 5)، مع أعداد النتائج الإيجابية الحقيقية والإيجابية الكاذبة والسلبية الكاذبة والسلبية الحقيقية لعشر دراسات، تضيف الهند (دراسة إيضاحية) وملاوي (طلب تقديم) وتنزانيا (طلب تقديم) إلى دراسات المعيار 1. وتتراوح الحساسية بين 0.62 (ملاوي) و0.91 (بيرو)، بينما تبلغ النوعية 0.90–1.00.",
        "zh": "TB-LAMP敏感性和特异性（含95%置信区间）森林图，以培养参考标准2为对照（图5），列出十项研究的TP、FP、FN和TN计数，在标准1的研究基础上增加了印度（示范研究）、马拉维（RFA）和坦桑尼亚（RFA）。敏感性从0.62（马拉维）到0.91（秘鲁）不等，特异性为0.90–1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad de la TB-LAMP, con intervalos de confianza del 95%, frente al patrón de referencia de cultivo 2 (figura 5), con los recuentos de VP, FP, FN y VN de diez estudios, que añaden la India (demostración), Malawi (RFA) y Tanzanía (RFA) a los del patrón 1. La sensibilidad varía de 0,62 (Malawi) a 0,91 (Perú), y la especificidad es de 0,90–1,00.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité du TB-LAMP, avec intervalles de confiance à 95 %, par rapport à la norme de référence par culture 2 (figure 5), avec le nombre de VP, FP, FN et VN pour dix études, ajoutant l'Inde (démonstration), le Malawi (RFA) et la Tanzanie (RFA) à celles de la norme 1. La sensibilité va de 0,62 (Malawi) à 0,91 (Pérou), et la spécificité est de 0,90–1,00.",
        "ru": "Лесовидный график чувствительности и специфичности TB-LAMP с 95% доверительными интервалами по сравнению с культуральным эталонным стандартом 2 (рисунок 5) с числом ИП, ЛП, ЛО и ИО для десяти исследований: к исследованиям стандарта 1 добавлены Индия (демонстрационное), Малави (RFA) и Танзания (RFA). Чувствительность колеблется от 0,62 (Малави) до 0,91 (Перу), а специфичность составляет 0,90–1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p030-3",
      "file": "images/img-p030-3.webp",
      "page": 30,
      "narratives": {
        "en": "Forest plot of TB-LAMP sensitivity and specificity with 95% confidence intervals against culture reference Standard 3 (Figure 5), with TP, FP, FN and TN counts for 13 studies, including India (RFA), Vietnam (RFA) and Ivory Coast (RFA). Sensitivity ranges widely from 0.48 (Vietnam RFA) to 1.00 (India RFA), while specificity stays between 0.90 and 1.00.",
        "ar": "مخطط غابي لحساسية اختبار TB-LAMP ونوعيته مع فترات ثقة 95% مقارنةً بمعيار الزرع المرجعي 3 (الشكل 5)، مع أعداد النتائج الإيجابية الحقيقية والإيجابية الكاذبة والسلبية الكاذبة والسلبية الحقيقية لـ13 دراسة، منها الهند (طلب تقديم) وفييت نام (طلب تقديم) وكوت ديفوار (طلب تقديم). وتتراوح الحساسية تراوحاً واسعاً بين 0.48 (فييت نام، طلب تقديم) و1.00 (الهند، طلب تقديم)، بينما تبقى النوعية بين 0.90 و1.00.",
        "zh": "TB-LAMP敏感性和特异性（含95%置信区间）森林图，以培养参考标准3为对照（图5），列出13项研究的TP、FP、FN和TN计数，包括印度（RFA）、越南（RFA）和科特迪瓦（RFA）。敏感性差异较大，从0.48（越南RFA）到1.00（印度RFA），特异性保持在0.90至1.00之间。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad de la TB-LAMP, con intervalos de confianza del 95%, frente al patrón de referencia de cultivo 3 (figura 5), con los recuentos de VP, FP, FN y VN de 13 estudios, entre ellos la India (RFA), Viet Nam (RFA) y Côte d'Ivoire (RFA). La sensibilidad varía ampliamente, de 0,48 (Viet Nam, RFA) a 1,00 (India, RFA), mientras que la especificidad se mantiene entre 0,90 y 1,00.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité du TB-LAMP, avec intervalles de confiance à 95 %, par rapport à la norme de référence par culture 3 (figure 5), avec le nombre de VP, FP, FN et VN pour 13 études, dont l'Inde (RFA), le Viet Nam (RFA) et la Côte d'Ivoire (RFA). La sensibilité varie largement, de 0,48 (Viet Nam, RFA) à 1,00 (Inde, RFA), tandis que la spécificité reste comprise entre 0,90 et 1,00.",
        "ru": "Лесовидный график чувствительности и специфичности TB-LAMP с 95% доверительными интервалами по сравнению с культуральным эталонным стандартом 3 (рисунок 5) с числом ИП, ЛП, ЛО и ИО для 13 исследований, включая Индию (RFA), Вьетнам (RFA) и Кот-д'Ивуар (RFA). Чувствительность сильно варьирует — от 0,48 (Вьетнам, RFA) до 1,00 (Индия, RFA), тогда как специфичность остается в пределах 0,90–1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p031-1",
      "file": "images/img-p031-1.webp",
      "page": 31,
      "narratives": {
        "en": "Forest plot of TB-LAMP sensitivity and specificity with 95% confidence intervals among adults living with HIV against culture reference Standard 1 (Figure 6), for two studies: South Africa (Eval), sensitivity 0.54 and specificity 1.00, and Uganda (RFA), sensitivity 0.58 and specificity 0.98.",
        "ar": "مخطط غابي لحساسية اختبار TB-LAMP ونوعيته مع فترات ثقة 95% بين البالغين المتعايشين مع فيروس العوز المناعي البشري مقارنةً بمعيار الزرع المرجعي 1 (الشكل 6)، لدراستين: جنوب أفريقيا (تقييم)، بحساسية 0.54 ونوعية 1.00، وأوغندا (طلب تقديم)، بحساسية 0.58 ونوعية 0.98.",
        "zh": "艾滋病毒感染成人中TB-LAMP敏感性和特异性（含95%置信区间）森林图，以培养参考标准1为对照（图6），涉及两项研究：南非（评估研究），敏感性0.54、特异性1.00；乌干达（RFA），敏感性0.58、特异性0.98。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad de la TB-LAMP, con intervalos de confianza del 95%, en adultos con el VIH frente al patrón de referencia de cultivo 1 (figura 6), para dos estudios: Sudáfrica (evaluación), sensibilidad 0,54 y especificidad 1,00, y Uganda (RFA), sensibilidad 0,58 y especificidad 0,98.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité du TB-LAMP, avec intervalles de confiance à 95 %, chez les adultes vivant avec le VIH par rapport à la norme de référence par culture 1 (figure 6), pour deux études : Afrique du Sud (évaluation), sensibilité 0,54 et spécificité 1,00, et Ouganda (RFA), sensibilité 0,58 et spécificité 0,98.",
        "ru": "Лесовидный график чувствительности и специфичности TB-LAMP с 95% доверительными интервалами среди взрослых, живущих с ВИЧ, по сравнению с культуральным эталонным стандартом 1 (рисунок 6) для двух исследований: Южная Африка (оценочное) — чувствительность 0,54, специфичность 1,00; Уганда (RFA) — чувствительность 0,58, специфичность 0,98."
      },
      "state": "draft"
    },
    {
      "id": "img-p031-2",
      "file": "images/img-p031-2.webp",
      "page": 31,
      "narratives": {
        "en": "Forest plot of TB-LAMP sensitivity and specificity with 95% confidence intervals among adults living with HIV against culture reference Standard 2 (Figure 6), for four studies (South Africa, Malawi, Tanzania, Uganda). Sensitivity ranges from 0.54 to 0.82 (Tanzania) and specificity from 0.75 (Tanzania, with a wide interval) to 1.00.",
        "ar": "مخطط غابي لحساسية اختبار TB-LAMP ونوعيته مع فترات ثقة 95% بين البالغين المتعايشين مع فيروس العوز المناعي البشري مقارنةً بمعيار الزرع المرجعي 2 (الشكل 6)، لأربع دراسات (جنوب أفريقيا وملاوي وتنزانيا وأوغندا). وتتراوح الحساسية بين 0.54 و0.82 (تنزانيا)، والنوعية بين 0.75 (تنزانيا، بفترة واسعة) و1.00.",
        "zh": "艾滋病毒感染成人中TB-LAMP敏感性和特异性（含95%置信区间）森林图，以培养参考标准2为对照（图6），涉及四项研究（南非、马拉维、坦桑尼亚、乌干达）。敏感性从0.54到0.82（坦桑尼亚），特异性从0.75（坦桑尼亚，区间较宽）到1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad de la TB-LAMP, con intervalos de confianza del 95%, en adultos con el VIH frente al patrón de referencia de cultivo 2 (figura 6), para cuatro estudios (Sudáfrica, Malawi, Tanzanía, Uganda). La sensibilidad varía de 0,54 a 0,82 (Tanzanía) y la especificidad de 0,75 (Tanzanía, con un intervalo amplio) a 1,00.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité du TB-LAMP, avec intervalles de confiance à 95 %, chez les adultes vivant avec le VIH par rapport à la norme de référence par culture 2 (figure 6), pour quatre études (Afrique du Sud, Malawi, Tanzanie, Ouganda). La sensibilité va de 0,54 à 0,82 (Tanzanie) et la spécificité de 0,75 (Tanzanie, avec un intervalle large) à 1,00.",
        "ru": "Лесовидный график чувствительности и специфичности TB-LAMP с 95% доверительными интервалами среди взрослых, живущих с ВИЧ, по сравнению с культуральным эталонным стандартом 2 (рисунок 6) для четырех исследований (Южная Африка, Малави, Танзания, Уганда). Чувствительность — от 0,54 до 0,82 (Танзания), специфичность — от 0,75 (Танзания, с широким интервалом) до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p031-3",
      "file": "images/img-p031-3.webp",
      "page": 31,
      "narratives": {
        "en": "Forest plot of TB-LAMP sensitivity and specificity with 95% confidence intervals among adults living with HIV against culture reference Standard 3 (Figure 6), for five studies (South Africa, Malawi, Tanzania, Uganda, Ivory Coast). Sensitivity ranges from 0.54 to 0.96 (Ivory Coast) and specificity from 0.33 (Ivory Coast) to 1.00.",
        "ar": "مخطط غابي لحساسية اختبار TB-LAMP ونوعيته مع فترات ثقة 95% بين البالغين المتعايشين مع فيروس العوز المناعي البشري مقارنةً بمعيار الزرع المرجعي 3 (الشكل 6)، لخمس دراسات (جنوب أفريقيا وملاوي وتنزانيا وأوغندا وكوت ديفوار). وتتراوح الحساسية بين 0.54 و0.96 (كوت ديفوار)، والنوعية بين 0.33 (كوت ديفوار) و1.00.",
        "zh": "艾滋病毒感染成人中TB-LAMP敏感性和特异性（含95%置信区间）森林图，以培养参考标准3为对照（图6），涉及五项研究（南非、马拉维、坦桑尼亚、乌干达、科特迪瓦）。敏感性从0.54到0.96（科特迪瓦），特异性从0.33（科特迪瓦）到1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad de la TB-LAMP, con intervalos de confianza del 95%, en adultos con el VIH frente al patrón de referencia de cultivo 3 (figura 6), para cinco estudios (Sudáfrica, Malawi, Tanzanía, Uganda, Côte d'Ivoire). La sensibilidad varía de 0,54 a 0,96 (Côte d'Ivoire) y la especificidad de 0,33 (Côte d'Ivoire) a 1,00.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité du TB-LAMP, avec intervalles de confiance à 95 %, chez les adultes vivant avec le VIH par rapport à la norme de référence par culture 3 (figure 6), pour cinq études (Afrique du Sud, Malawi, Tanzanie, Ouganda, Côte d'Ivoire). La sensibilité va de 0,54 à 0,96 (Côte d'Ivoire) et la spécificité de 0,33 (Côte d'Ivoire) à 1,00.",
        "ru": "Лесовидный график чувствительности и специфичности TB-LAMP с 95% доверительными интервалами среди взрослых, живущих с ВИЧ, по сравнению с культуральным эталонным стандартом 3 (рисунок 6) для пяти исследований (Южная Африка, Малави, Танзания, Уганда, Кот-д'Ивуар). Чувствительность — от 0,54 до 0,96 (Кот-д'Ивуар), специфичность — от 0,33 (Кот-д'Ивуар) до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p031",
      "file": "figures/vfig-p031.webp",
      "page": 31,
      "shows": [
        "Figure 6",
        "Table 4"
      ],
      "narratives": {
        "en": "Render of a report page showing the end of Table 4 (pooled sensitivity 77.7%, 76.0% and 80.3% and pooled specificity 98.1%, 98.0% and 97.7% for reference Standards 1–3) followed by Figure 6: forest plots of TB-LAMP sensitivity and specificity among adults living with HIV against Standards 1, 2 and 3, with two, four and five studies respectively. Individual-study sensitivity ranges from 0.54 to 0.96 and specificity from 0.33 to 1.00.",
        "ar": "عرض لصفحة من التقرير يبيّن نهاية الجدول 4 (الحساسية المجمّعة 77.7% و76.0% و80.3% والنوعية المجمّعة 98.1% و98.0% و97.7% للمعايير المرجعية 1–3)، يليه الشكل 6: مخططات غابية لحساسية اختبار TB-LAMP ونوعيته بين البالغين المتعايشين مع فيروس العوز المناعي البشري مقارنةً بالمعايير 1 و2 و3، بدراستين وأربع دراسات وخمس دراسات على التوالي. وتتراوح الحساسية في الدراسات الفردية بين 0.54 و0.96، والنوعية بين 0.33 و1.00.",
        "zh": "报告页面渲染图，显示表4末尾（参考标准1–3的合并敏感性分别为77.7%、76.0%和80.3%，合并特异性分别为98.1%、98.0%和97.7%），其后为图6：艾滋病毒感染成人中TB-LAMP相对于标准1、2和3的敏感性和特异性森林图，分别涉及两项、四项和五项研究。单项研究的敏感性为0.54至0.96，特异性为0.33至1.00。",
        "es": "Representación de una página del informe que muestra el final del cuadro 4 (sensibilidad combinada del 77,7%, 76,0% y 80,3% y especificidad combinada del 98,1%, 98,0% y 97,7% para los patrones de referencia 1–3), seguido de la figura 6: diagramas de bosque de la sensibilidad y la especificidad de la TB-LAMP en adultos con el VIH frente a los patrones 1, 2 y 3, con dos, cuatro y cinco estudios, respectivamente. La sensibilidad de cada estudio varía de 0,54 a 0,96 y la especificidad de 0,33 a 1,00.",
        "fr": "Rendu d'une page du rapport montrant la fin du tableau 4 (sensibilité groupée de 77,7 %, 76,0 % et 80,3 % et spécificité groupée de 98,1 %, 98,0 % et 97,7 % pour les normes de référence 1 à 3), suivie de la figure 6 : graphiques en forêt de la sensibilité et de la spécificité du TB-LAMP chez les adultes vivant avec le VIH par rapport aux normes 1, 2 et 3, avec respectivement deux, quatre et cinq études. La sensibilité par étude va de 0,54 à 0,96 et la spécificité de 0,33 à 1,00.",
        "ru": "Изображение страницы доклада: окончание таблицы 4 (объединенная чувствительность 77,7%, 76,0% и 80,3% и объединенная специфичность 98,1%, 98,0% и 97,7% для эталонных стандартов 1–3), за которым следует рисунок 6 — лесовидные графики чувствительности и специфичности TB-LAMP среди взрослых, живущих с ВИЧ, по сравнению со стандартами 1, 2 и 3 (соответственно два, четыре и пять исследований). Чувствительность в отдельных исследованиях — от 0,54 до 0,96, специфичность — от 0,33 до 1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p033-1",
      "file": "images/img-p033-1.webp",
      "page": 33,
      "narratives": {
        "en": "Forest plot of TB-LAMP sensitivity and specificity with 95% confidence intervals as an add-on test following negative sputum-smear microscopy, against culture reference Standard 1 (Figure 7), for seven studies. Sensitivity is low and variable, from 0.19 (Haiti) to 0.78 (Peru), while specificity is 0.90–1.00.",
        "ar": "مخطط غابي لحساسية اختبار TB-LAMP ونوعيته مع فترات ثقة 95% كاختبار إضافي بعد سلبية الفحص المجهري للطاخة البلغم، مقارنةً بمعيار الزرع المرجعي 1 (الشكل 7)، لسبع دراسات. والحساسية منخفضة ومتفاوتة، من 0.19 (هايتي) إلى 0.78 (بيرو)، بينما تبلغ النوعية 0.90–1.00.",
        "zh": "TB-LAMP作为痰涂片镜检阴性后附加检测的敏感性和特异性（含95%置信区间）森林图，以培养参考标准1为对照（图7），涉及七项研究。敏感性较低且差异大，从0.19（海地）到0.78（秘鲁），特异性为0.90–1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad de la TB-LAMP, con intervalos de confianza del 95%, como prueba complementaria tras una baciloscopia de esputo negativa, frente al patrón de referencia de cultivo 1 (figura 7), para siete estudios. La sensibilidad es baja y variable, de 0,19 (Haití) a 0,78 (Perú), mientras que la especificidad es de 0,90–1,00.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité du TB-LAMP, avec intervalles de confiance à 95 %, en tant que test complémentaire après un examen microscopique des frottis d'expectoration négatif, par rapport à la norme de référence par culture 1 (figure 7), pour sept études. La sensibilité est faible et variable, de 0,19 (Haïti) à 0,78 (Pérou), tandis que la spécificité est de 0,90–1,00.",
        "ru": "Лесовидный график чувствительности и специфичности TB-LAMP с 95% доверительными интервалами в качестве дополнительного теста после отрицательного результата микроскопии мазка мокроты по сравнению с культуральным эталонным стандартом 1 (рисунок 7) для семи исследований. Чувствительность низкая и вариабельная — от 0,19 (Гаити) до 0,78 (Перу), а специфичность составляет 0,90–1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p033-2",
      "file": "images/img-p033-2.webp",
      "page": 33,
      "narratives": {
        "en": "Forest plot of TB-LAMP sensitivity and specificity with 95% confidence intervals as an add-on test following negative sputum-smear microscopy, against culture reference Standard 2 (Figure 7), for nine studies. Sensitivity ranges from 0.17 (Tanzania) to 0.81 (India Demo), while specificity is 0.90–1.00.",
        "ar": "مخطط غابي لحساسية اختبار TB-LAMP ونوعيته مع فترات ثقة 95% كاختبار إضافي بعد سلبية الفحص المجهري للطاخة البلغم، مقارنةً بمعيار الزرع المرجعي 2 (الشكل 7)، لتسع دراسات. وتتراوح الحساسية بين 0.17 (تنزانيا) و0.81 (الهند، دراسة إيضاحية)، بينما تبلغ النوعية 0.90–1.00.",
        "zh": "TB-LAMP作为痰涂片镜检阴性后附加检测的敏感性和特异性（含95%置信区间）森林图，以培养参考标准2为对照（图7），涉及九项研究。敏感性从0.17（坦桑尼亚）到0.81（印度示范研究），特异性为0.90–1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad de la TB-LAMP, con intervalos de confianza del 95%, como prueba complementaria tras una baciloscopia de esputo negativa, frente al patrón de referencia de cultivo 2 (figura 7), para nueve estudios. La sensibilidad varía de 0,17 (Tanzanía) a 0,81 (India, demostración), mientras que la especificidad es de 0,90–1,00.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité du TB-LAMP, avec intervalles de confiance à 95 %, en tant que test complémentaire après un examen microscopique des frottis d'expectoration négatif, par rapport à la norme de référence par culture 2 (figure 7), pour neuf études. La sensibilité va de 0,17 (Tanzanie) à 0,81 (Inde, démonstration), tandis que la spécificité est de 0,90–1,00.",
        "ru": "Лесовидный график чувствительности и специфичности TB-LAMP с 95% доверительными интервалами в качестве дополнительного теста после отрицательного результата микроскопии мазка мокроты по сравнению с культуральным эталонным стандартом 2 (рисунок 7) для девяти исследований. Чувствительность — от 0,17 (Танзания) до 0,81 (Индия, демонстрационное), специфичность — 0,90–1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p034-1",
      "file": "images/img-p034-1.webp",
      "page": 34,
      "narratives": {
        "en": "Forest plot of TB-LAMP sensitivity and specificity with 95% confidence intervals as an add-on test following negative sputum-smear microscopy, against culture reference Standard 3 (Figure 7, continued), for 11 studies. Sensitivity ranges from 0.17 (Tanzania) to 0.81 (India Demo), while specificity is 0.90–1.00.",
        "ar": "مخطط غابي لحساسية اختبار TB-LAMP ونوعيته مع فترات ثقة 95% كاختبار إضافي بعد سلبية الفحص المجهري للطاخة البلغم، مقارنةً بمعيار الزرع المرجعي 3 (تابع الشكل 7)، لـ11 دراسة. وتتراوح الحساسية بين 0.17 (تنزانيا) و0.81 (الهند، دراسة إيضاحية)، بينما تبلغ النوعية 0.90–1.00.",
        "zh": "TB-LAMP作为痰涂片镜检阴性后附加检测的敏感性和特异性（含95%置信区间）森林图，以培养参考标准3为对照（图7续），涉及11项研究。敏感性从0.17（坦桑尼亚）到0.81（印度示范研究），特异性为0.90–1.00。",
        "es": "Diagrama de bosque de la sensibilidad y la especificidad de la TB-LAMP, con intervalos de confianza del 95%, como prueba complementaria tras una baciloscopia de esputo negativa, frente al patrón de referencia de cultivo 3 (continuación de la figura 7), para 11 estudios. La sensibilidad varía de 0,17 (Tanzanía) a 0,81 (India, demostración), mientras que la especificidad es de 0,90–1,00.",
        "fr": "Graphique en forêt de la sensibilité et de la spécificité du TB-LAMP, avec intervalles de confiance à 95 %, en tant que test complémentaire après un examen microscopique des frottis d'expectoration négatif, par rapport à la norme de référence par culture 3 (suite de la figure 7), pour 11 études. La sensibilité va de 0,17 (Tanzanie) à 0,81 (Inde, démonstration), tandis que la spécificité est de 0,90–1,00.",
        "ru": "Лесовидный график чувствительности и специфичности TB-LAMP с 95% доверительными интервалами в качестве дополнительного теста после отрицательного результата микроскопии мазка мокроты по сравнению с культуральным эталонным стандартом 3 (продолжение рисунка 7) для 11 исследований. Чувствительность — от 0,17 (Танзания) до 0,81 (Индия, демонстрационное), специфичность — 0,90–1,00."
      },
      "state": "draft"
    },
    {
      "id": "img-p052-1",
      "file": "images/img-p052-1.webp",
      "page": 52,
      "narratives": {
        "en": "An ISBN barcode with the number 9 789241 511186 printed beneath it.",
        "ar": "رمز شريطي للرقم الدولي المعياري للكتاب (ISBN) مطبوع تحته الرقم 9 789241 511186.",
        "zh": "国际标准书号（ISBN）条形码，下方印有号码 9 789241 511186。",
        "es": "Un código de barras del ISBN con el número 9 789241 511186 impreso debajo.",
        "fr": "Un code-barres ISBN avec le numéro 9 789241 511186 imprimé en dessous.",
        "ru": "Штрихкод ISBN с напечатанным под ним номером 9 789241 511186."
      },
      "state": "draft"
    }
  ],
  "tables": [
    {
      "label": "Table 1",
      "caption": "Table 1. Characteristics for all studies included in the evaluation of TB-LAMP (see Annex 1 for information about the studies)",
      "pages": [
        26
      ],
      "columns": [
        {
          "titles": "Study"
        },
        {
          "titles": "Health system level"
        },
        {
          "titles": "Microscopy type"
        },
        {
          "titles": "TB culture type"
        },
        {
          "titles": "MGIT contamination rate (%)"
        },
        {
          "titles": "Type of test done on stored sputum"
        },
        {
          "titles": "Xpert MTB/RIF specimen type"
        },
        {
          "titles": "Median age (years) of participants (IQR)"
        },
        {
          "titles": "Female (%)"
        },
        {
          "titles": "HIV-negativea (%)"
        },
        {
          "titles": "Culture-positive TBb (%)"
        },
        {
          "titles": "Smear-negative TBc (%)"
        }
      ],
      "rows": [
        [
          "Brazil (EVAL)",
          "Reference Laboratory",
          "2 direct ZN",
          "2 MGIT, 2 LJ",
          "0",
          "Xpert; culture",
          "Frozen processed",
          "48 (35-60)",
          "40",
          "0.4",
          "32",
          "25"
        ],
        [
          "Peru (EVAL)",
          "Reference Laboratory",
          "2 direct ZN",
          "2 MGIT, 2 LJ",
          "1.3",
          "Xpert; culture",
          "Fresh processed",
          "43 (28-56)",
          "50",
          "1.0",
          "22",
          "42"
        ],
        [
          "S. Africa (EVAL)",
          "Reference Laboratory",
          "2 direct ZN",
          "2 MGIT, 2 LJ",
          "3.1",
          "Xpert; culture",
          "Fresh processed",
          "39 (29-47)",
          "34",
          "35",
          "26",
          "51"
        ],
        [
          "Vietnam (EVAL)",
          "Reference Laboratory",
          "2 direct ZN",
          "2 MGIT, 2 LJ",
          "0",
          "Xpert; culture",
          "Frozen processed",
          "39 (26-50)",
          "30",
          "2",
          "66",
          "42"
        ],
        [
          "India (DEMO)",
          "Microscopy centre",
          "2 direct ZN",
          "MGIT, LJ",
          "6.5",
          "Culture",
          "None",
          "40 (27-51)",
          "35",
          "2",
          "11",
          "25"
        ],
        [
          "India (RFA)",
          "University-affiliated DOTS clinic",
          "1 direct ZN",
          "MGIT",
          "11.5",
          "Xpert; culture",
          "Frozen processed",
          "43 (29-55)",
          "37",
          "2",
          "15",
          "54c"
        ],
        [
          "Vietnam (RFA)",
          "Microscopy centre",
          "2 direct ZN",
          "MGIT",
          "0",
          "Xpert; culture",
          "Fresh processed",
          "60 (52-70)",
          "42",
          "0.5",
          "8",
          "59"
        ],
        [
          "Malawi (RFA)",
          "Microscopy centre",
          "1 direct FM",
          "MGIT, LJ",
          "8.7",
          "Xpert; culture",
          "Fresh direct",
          "35 (26-41)",
          "48",
          "44",
          "16",
          "15c"
        ],
        [
          "Tanzania (RFA)",
          "District hospital TB clinic",
          "2 direct FM",
          "MGIT, LJ",
          "5.1",
          "Culture",
          "Fresh direct",
          "37 (28-46)",
          "45",
          "6",
          "29",
          "28"
        ],
        [
          "Uganda (RFA)",
          "District hospital outpatient clinic",
          "2 direct FM",
          "2 MGIT, 2 LJ",
          "1.3",
          "Culture",
          "Fresh direct",
          "43 (30-54)",
          "43",
          "48",
          "31",
          "45"
        ],
        [
          "Ivory Coast (RFA)",
          "District hospital outpatient clinic",
          "2 direct ZN",
          "MGIT",
          "6.0",
          "Xpert Culture",
          "Fresh processed",
          "38 (28-44)",
          "51",
          "12",
          "33",
          "13"
        ],
        [
          "Madagascar (RFA)",
          "University-affiliated DOTS clinic",
          "2 direct FM",
          "2 LJ",
          "–",
          "Xpert Culture",
          "Fresh direct",
          "42 (29-52)",
          "40",
          "–",
          "37",
          "27"
        ],
        [
          "Haiti",
          "Urban hospital outpatient clinic",
          "2 direct FM",
          "3 MGIT",
          "0",
          "Culture",
          "None",
          "–",
          "–",
          "–",
          "34",
          "23"
        ]
      ],
      "notes": "– Indicates that information was not available. DEMO: demonstration study conducted in the setting of intended use; EVAL: evaluation study conducted in a reference laboratory; FM: fluorescence microscopy; IQR: interquartile range; LJ: Löwenstein–Jensen culture; MGIT, mycobacterial growth indicator tube culture (BACTEC MGIT, Becton Dickinson, Franklin Lakes, NJ, United States); RFA: request for application; Xpert: Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, United States); ZN, Ziehl–Neelsen stain. a HIV status was unknown and counted as negative. This reflects the proportion of a study’s population that was known to be HIV-positive. b The reference standard used for this calculation was Standard 3 for all studies. c Smear microscopy results were based on the analysis of only one smear.",
      "narratives": {
        "en": "The table describes the 13 studies included in the evaluation of TB-LAMP, by country and study type. For each study it gives the health system level, microscopy and culture methods, MGIT contamination rate, tests done on stored sputum, Xpert MTB/RIF specimen type, participants’ median age, the percentages female and HIV-negative, and the percentages with culture-positive and smear-negative TB.",
        "ar": "يصف الجدول الدراسات الثلاث عشرة المدرجة في تقييم اختبار TB-LAMP حسب البلد ونوع الدراسة. ويعرض لكل دراسة مستوى النظام الصحي، وطرق الفحص المجهري والزرع، ومعدل تلوث مزارع MGIT، والاختبارات المجراة على البلغم المخزن، ونوع عينة Xpert MTB/RIF، والعمر الوسيط للمشاركين، ونسبتي الإناث وسلبيي فيروس العوز المناعي البشري، ونسبتي حالات السل المؤكدة بالزرع وسلبية اللطاخة.",
        "zh": "本表按国家和研究类型介绍了纳入TB-LAMP评价的13项研究。对每项研究，给出了卫生系统层级、显微镜检查和培养方法、MGIT污染率、对储存痰标本所做的检测、Xpert MTB/RIF标本类型、参与者年龄中位数、女性和艾滋病毒阴性者比例，以及培养阳性结核和涂片阴性结核的比例。",
        "es": "El cuadro describe los 13 estudios incluidos en la evaluación de la TB-LAMP, por país y tipo de estudio. Para cada estudio indica el nivel del sistema de salud, los métodos de microscopía y cultivo, la tasa de contaminación MGIT, las pruebas realizadas en esputo almacenado, el tipo de muestra para Xpert MTB/RIF, la mediana de edad de los participantes, los porcentajes de mujeres y de personas VIH-negativas, y los porcentajes de TB con cultivo positivo y con baciloscopia negativa.",
        "fr": "Le tableau décrit les 13 études incluses dans l’évaluation du TB-LAMP, par pays et type d’étude. Pour chaque étude, il indique le niveau du système de santé, les méthodes de microscopie et de culture, le taux de contamination MGIT, les tests réalisés sur les expectorations conservées, le type d’échantillon Xpert MTB/RIF, l’âge médian des participants, les pourcentages de femmes et de personnes séronégatives pour le VIH, et les pourcentages de TB confirmée par culture et à frottis négatif.",
        "ru": "В таблице описаны 13 исследований, включённых в оценку TB-LAMP, с разбивкой по странам и типам исследований. Для каждого исследования указаны уровень системы здравоохранения, методы микроскопии и посева, частота контаминации MGIT, тесты на хранившейся мокроте, тип образца для Xpert MTB/RIF, медианный возраст участников, доля женщин и ВИЧ-отрицательных лиц, а также доля случаев ТБ с положительным посевом и с отрицательным мазком."
      },
      "csv": "tables/table-1.csv"
    },
    {
      "label": "Table 2",
      "caption": "Table 2. Risk of bias and applicability concerns: review authors’ judgements about each domain (see Annex 1 for information about the studies)",
      "pages": [
        27
      ],
      "columns": [
        {
          "titles": "Study"
        },
        {
          "titles": "Patient selection",
          "group": "Risk of bias"
        },
        {
          "titles": "Index test",
          "group": "Risk of bias"
        },
        {
          "titles": "Reference standard",
          "group": "Risk of bias"
        },
        {
          "titles": "Flow and timing",
          "group": "Risk of bias"
        },
        {
          "titles": "Patient selection",
          "group": "Applicability concerns"
        },
        {
          "titles": "Index test",
          "group": "Applicability concerns"
        },
        {
          "titles": "Reference standard",
          "group": "Applicability concerns"
        }
      ],
      "rows": [
        [
          "Brazil (EVAL)",
          "LOW",
          "LOW",
          "HIGH",
          "LOW",
          "HIGH",
          "LOW",
          "LOW"
        ],
        [
          "Peru (EVAL)",
          "LOW",
          "LOW",
          "HIGH",
          "LOW",
          "HIGH",
          "LOW",
          "LOW"
        ],
        [
          "South Africa (EVAL)",
          "LOW",
          "LOW",
          "HIGH",
          "LOW",
          "HIGH",
          "LOW",
          "LOW"
        ],
        [
          "Vietnam (EVAL)",
          "LOW",
          "LOW",
          "HIGH",
          "LOW",
          "HIGH",
          "LOW",
          "LOW"
        ],
        [
          "India (DEMO)",
          "LOW",
          "LOW",
          "HIGH",
          "LOW",
          "LOW",
          "LOW",
          "LOW"
        ],
        [
          "India (RFA)",
          "UNCLEAR",
          "LOW",
          "HIGH",
          "UNCLEAR",
          "LOW",
          "LOW",
          "LOW"
        ],
        [
          "Vietnam (RFA)",
          "UNCLEAR",
          "LOW",
          "HIGH",
          "UNCLEAR",
          "LOW",
          "LOW",
          "LOW"
        ],
        [
          "Malawi (RFA)",
          "LOW",
          "LOW",
          "HIGH",
          "HIGH",
          "LOW",
          "LOW",
          "LOW"
        ],
        [
          "United Republic of Tanzania (RFA)",
          "UNCLEAR",
          "LOW",
          "HIGH",
          "UNCLEAR",
          "HIGH",
          "LOW",
          "LOW"
        ],
        [
          "Uganda (RFA)",
          "UNCLEAR",
          "LOW",
          "HIGH",
          "UNCLEAR",
          "LOW",
          "LOW",
          "LOW"
        ],
        [
          "Côte d’Ivoire (RFA)",
          "LOW",
          "LOW",
          "HIGH",
          "UNCLEAR",
          "LOW",
          "LOW",
          "LOW"
        ],
        [
          "Madagascar (RFA)",
          "LOW",
          "LOW",
          "HIGH",
          "UNCLEAR",
          "LOW",
          "LOW",
          "LOW"
        ],
        [
          "Haiti (unpublished)",
          "UNCLEAR",
          "LOW",
          "HIGH",
          "UNCLEAR",
          "LOW",
          "LOW",
          "LOW"
        ]
      ],
      "notes": "DEMO: demonstration study conducted in the setting of intended use; EVAL: evaluation study conducted in a reference laboratory; RFA: request for applications.",
      "narratives": {
        "en": "The table gives the review authors’ QUADAS-2 judgements (low, high or unclear) for each of the 13 TB-LAMP studies: risk of bias in four domains (patient selection, index test, reference standard, flow and timing) and applicability concerns in three domains.",
        "ar": "يعرض الجدول أحكام مؤلفي المراجعة وفق أداة QUADAS-2 (منخفض أو مرتفع أو غير واضح) لكل دراسة من دراسات TB-LAMP الثلاث عشرة: خطر التحيز في أربعة مجالات (اختيار المرضى، والاختبار المؤشر، والمعيار المرجعي، والتدفق والتوقيت) والمخاوف المتعلقة بقابلية التطبيق في ثلاثة مجالات.",
        "zh": "本表列出了综述作者按QUADAS-2工具对13项TB-LAMP研究所作的判断（低、高或不明确）：四个领域（患者选择、待评价试验、参考标准、流程和时间）的偏倚风险，以及三个领域的适用性问题。",
        "es": "El cuadro presenta las valoraciones QUADAS-2 de los autores de la revisión (bajo, alto o incierto) para cada uno de los 13 estudios de la TB-LAMP: riesgo de sesgo en cuatro dominios (selección de pacientes, prueba índice, patrón de referencia, flujo y cronología) y problemas de aplicabilidad en tres dominios.",
        "fr": "Le tableau présente les jugements QUADAS-2 des auteurs de la revue (faible, élevé ou incertain) pour chacune des 13 études du TB-LAMP : risque de biais dans quatre domaines (sélection des patients, test index, norme de référence, flux et calendrier) et préoccupations quant à l’applicabilité dans trois domaines.",
        "ru": "В таблице приведены оценки авторов обзора по инструменту QUADAS-2 (низкий, высокий или неясный) для каждого из 13 исследований TB-LAMP: риск систематической ошибки в четырёх доменах (отбор пациентов, индексный тест, эталонный стандарт, поток и сроки) и вопросы применимости в трёх доменах."
      },
      "csv": "tables/table-2.csv"
    },
    {
      "label": "Table 3",
      "caption": "Table 3. TB-LAMP as a replacement test for smear microscopy: eligible and included patients, by reference standard and study site (see Annex 1 for information about the studies)",
      "pages": [
        29
      ],
      "columns": [
        {
          "titles": "Study"
        },
        {
          "titles": "Total number of participants"
        },
        {
          "titles": "Number of participants eligiblea"
        },
        {
          "titles": "Standard 1",
          "group": "Number (%) includedb"
        },
        {
          "titles": "Standard 2",
          "group": "Number (%) includedb"
        },
        {
          "titles": "Standard 3",
          "group": "Number (%) includedb"
        }
      ],
      "rows": [
        [
          "Brazil (EVAL)",
          "266",
          "239",
          "237 (99)",
          "237 (99)",
          "237 (99)"
        ],
        [
          "Peru (EVAL)",
          "199",
          "198",
          "198 (100)",
          "198 (100)",
          "198 (100)"
        ],
        [
          "South Africa (EVAL)",
          "259",
          "240",
          "237 (99)",
          "237 (99)",
          "238 (99)"
        ],
        [
          "Vietnam (EVAL)",
          "312",
          "304",
          "304 (100)",
          "304 (100)",
          "304 (100)"
        ],
        [
          "India (DEMO)",
          "619",
          "598",
          "–",
          "559 (94)",
          "586 (98)"
        ],
        [
          "India (RFA)",
          "530",
          "504",
          "–",
          "–",
          "446 (89)"
        ],
        [
          "Vietnam (RFA)",
          "503",
          "364",
          "–",
          "–",
          "361 (99)"
        ],
        [
          "Malawi (RFA)",
          "273",
          "265",
          "–",
          "149 (56)",
          "234 (88)"
        ],
        [
          "Unite Republic of Tanzania (RFA)",
          "648",
          "648",
          "–",
          "587 (91)",
          "632 (98)"
        ],
        [
          "Uganda (RFA)",
          "233",
          "190",
          "184 (97)",
          "189 (99)",
          "190 (100)"
        ],
        [
          "Côte d’Ivoire (RFA)",
          "500",
          "480",
          "–",
          "–",
          "451 (94)"
        ],
        [
          "Madagascar (RFA)",
          "548",
          "521",
          "476 (91)",
          "476 (91)",
          "516 (99)"
        ],
        [
          "Haiti (unpublished)",
          "209",
          "209",
          "174 (83)",
          "174 (83)",
          "203 (97)"
        ],
        [
          "Total",
          "5 099",
          "4 760",
          "1 810 (38)",
          "3 110 (65)",
          "4 596 (97)"
        ]
      ],
      "notes": "– Indicates that reference standard criteria were not met by at least 5 TB patients and 5 non-TB patients. DEMO: demonstration study conducted in the setting of intended use; EVAL: evaluation study conducted in a reference laboratory; RFA: request for application. a The total number eligible includes those with missing or indeterminate TB-LAMP results: Brazil EVAL (n = 2 indeterminate), South Africa EVAL (n = 2 indeterminate), Madagascar RFA (n = 1 missing, n = 1 indeterminate), Malawi RFA (n = 5 missing), United Republic of Tanzania RFA (n = 11 missing), Haiti unpublished (n = 6 missing). b All reference standards classify patients as having TB if ≥ 1 positive culture was confirmed as M. tuberculosis by speciation testing. To be classified as not having TB, patients had to have no positive and at least (i) two negative cultures on two different sputum specimens (Standard 1), (ii) two negative cultures on the same or different sputum specimens (Standard 2), or (iii) at least one negative culture (Standard 3).",
      "narratives": {
        "en": "For the analysis of TB-LAMP as a replacement for smear microscopy, the table gives for each of the 13 study sites the total number of participants, the number eligible and the number (%) included under each of three culture-based reference standards, with totals.",
        "ar": "بالنسبة لتحليل اختبار TB-LAMP كبديل للفحص المجهري للطاخة، يعرض الجدول لكل موقع من مواقع الدراسة الثلاثة عشر العدد الإجمالي للمشاركين، وعدد المؤهلين، وعدد (نسبة) المدرجين وفق كل معيار من المعايير المرجعية الثلاثة القائمة على الزرع، مع المجاميع.",
        "zh": "针对以TB-LAMP替代涂片显微镜检查的分析，本表按13个研究地点分别列出参与者总数、符合条件人数，以及在三种基于培养的参考标准下各自纳入的人数（%），并给出合计。",
        "es": "Para el análisis de la TB-LAMP como sustituto de la baciloscopia, el cuadro indica para cada uno de los 13 centros de estudio el número total de participantes, el número de participantes elegibles y el número (%) de incluidos según cada uno de los tres patrones de referencia basados en el cultivo, con los totales.",
        "fr": "Pour l’analyse du TB-LAMP en remplacement de la microscopie des frottis, le tableau indique pour chacun des 13 sites d’étude le nombre total de participants, le nombre de participants éligibles et le nombre (%) inclus selon chacune des trois normes de référence fondées sur la culture, avec les totaux.",
        "ru": "Для анализа TB-LAMP в качестве замены микроскопии мазка в таблице по каждому из 13 исследовательских центров приведены общее число участников, число соответствующих критериям и число (%) включённых по каждому из трёх эталонных стандартов на основе посева, а также итоговые значения."
      },
      "csv": "tables/table-3.csv"
    },
    {
      "label": "Table 4",
      "caption": "Table 4. TB-LAMP as a replacement test for smear microscopy: estimates of pooled sensitivity and specificity",
      "pages": [
        31
      ],
      "columns": [
        {
          "titles": "Reference standarda"
        },
        {
          "titles": "Pooled sensitivityb"
        },
        {
          "titles": "Pooled specificityb"
        }
      ],
      "rows": [
        [
          "Standard 1",
          "77.7 (71.2-83.0)",
          "98.1 (95.7-99.2)"
        ],
        [
          "Standard 2",
          "76.0 (69.9-81.2)",
          "98.0 (96.0-99.0)"
        ],
        [
          "Standard 3",
          "80.3 (70.3-87.5)",
          "97.7 (96.1-98.7)"
        ]
      ],
      "notes": "a All reference standards classify patients as having TB if ≥ 1 positive culture was confirmed as M. tuberculosis by speciation testing. To be classified as not having TB, patients had to have no positive and at least (i) two negative cultures on two different sputum specimens (Standard 1), (ii) two negative cultures on the same or different sputum specimens (Standard 2), or (iii) at least one negative culture (Standard 3). b Values are percentages (95% confidence intervals).",
      "narratives": {
        "en": "The table gives the pooled sensitivity and specificity, as percentages with 95% confidence intervals, of TB-LAMP used as a replacement test for smear microscopy against each of three culture-based reference standards.",
        "ar": "يعرض الجدول الحساسية والنوعية المجمعتين، كنسب مئوية مع فترات ثقة 95%، لاختبار TB-LAMP المستخدم كبديل للفحص المجهري للطاخة، مقارنةً بكل معيار من المعايير المرجعية الثلاثة القائمة على الزرع.",
        "zh": "本表列出了以TB-LAMP替代涂片显微镜检查时，相对于三种基于培养的参考标准的合并敏感度和特异度（百分比及95%置信区间）。",
        "es": "El cuadro presenta la sensibilidad y la especificidad agrupadas, en porcentajes con intervalos de confianza del 95%, de la TB-LAMP utilizada como sustituto de la baciloscopia, frente a cada uno de los tres patrones de referencia basados en el cultivo.",
        "fr": "Le tableau présente la sensibilité et la spécificité poolées, en pourcentages avec intervalles de confiance à 95 %, du TB-LAMP utilisé en remplacement de la microscopie des frottis, par rapport à chacune des trois normes de référence fondées sur la culture.",
        "ru": "В таблице приведены объединённые чувствительность и специфичность (в процентах с 95% доверительными интервалами) TB-LAMP, используемого вместо микроскопии мазка, по сравнению с каждым из трёх эталонных стандартов на основе посева."
      },
      "csv": "tables/table-4.csv"
    },
    {
      "label": "Table 5",
      "caption": "Table 5. TB-LAMP as a replacement test for smear microscopy in persons living with HIV: pooled sensitivity and specificity",
      "pages": [
        32
      ],
      "columns": [
        {
          "titles": "Reference standarda"
        },
        {
          "titles": "Pooled sensitivityb"
        },
        {
          "titles": "Pooled specificityb"
        }
      ],
      "rows": [
        [
          "Standard 1",
          "NA",
          "NA"
        ],
        [
          "Standard 2",
          "63.8 (49.0-76.4)",
          "98.8 (85.1-99.9)"
        ],
        [
          "Standard 3",
          "73.4 (51.9-87.6)",
          "95.0 (64.0-99.5)"
        ]
      ],
      "notes": "NA: not applicable because < 4 studies were eligible. a All reference standards classify patients as having TB if ≥ 1 positive culture was confirmed as M. tuberculosis by speciation testing. To be classified as not having TB, patients were required to have no positive and at least (i) two negative cultures on two different sputum specimens (Standard 1), (ii) two negative cultures on the same or different sputum specimens (Standard 2), or (iii) at least one negative culture (Standard 3). b Values are percentages (95% confidence intervals).",
      "narratives": {
        "en": "The table gives the pooled sensitivity and specificity, as percentages with 95% confidence intervals, of TB-LAMP used as a replacement test for smear microscopy in persons living with HIV (not estimated for Standard 1 because fewer than 4 studies were eligible) against each of three culture-based reference standards.",
        "ar": "يعرض الجدول الحساسية والنوعية المجمعتين، كنسب مئوية مع فترات ثقة 95%، لاختبار TB-LAMP المستخدم كبديل للفحص المجهري للطاخة لدى المتعايشين مع فيروس العوز المناعي البشري، مقارنةً بكل معيار من المعايير المرجعية الثلاثة القائمة على الزرع (لم تُقدَّر للمعيار 1 لأن عدد الدراسات المؤهلة كان أقل من 4).",
        "zh": "本表列出了在艾滋病毒感染者中以TB-LAMP替代涂片显微镜检查时，相对于三种基于培养的参考标准的合并敏感度和特异度（百分比及95%置信区间）；标准1因符合条件的研究少于4项而未作估计。",
        "es": "El cuadro presenta la sensibilidad y la especificidad agrupadas, en porcentajes con intervalos de confianza del 95%, de la TB-LAMP utilizada como sustituto de la baciloscopia en personas con VIH, frente a cada uno de los tres patrones de referencia basados en el cultivo (sin estimación para el patrón 1 por haber menos de 4 estudios elegibles).",
        "fr": "Le tableau présente la sensibilité et la spécificité poolées, en pourcentages avec intervalles de confiance à 95 %, du TB-LAMP utilisé en remplacement de la microscopie des frottis chez les personnes vivant avec le VIH, par rapport à chacune des trois normes de référence fondées sur la culture (pas d’estimation pour la norme 1, moins de 4 études étant éligibles).",
        "ru": "В таблице приведены объединённые чувствительность и специфичность (в процентах с 95% доверительными интервалами) TB-LAMP, используемого вместо микроскопии мазка у людей, живущих с ВИЧ, по сравнению с каждым из трёх эталонных стандартов на основе посева (для стандарта 1 оценка не проводилась, так как подходящих исследований было менее 4)."
      },
      "csv": "tables/table-5.csv"
    },
    {
      "label": "Table 6",
      "caption": "Table 6. TB-LAMP as an add-on test following negative sputum-smear microscopy: eligible and included patients, by reference standard and study site (see Annex 1 for information about the studies)",
      "pages": [
        32,
        33
      ],
      "columns": [
        {
          "titles": "Study"
        },
        {
          "titles": "Total number of participants"
        },
        {
          "titles": "Number of participants eligiblea"
        },
        {
          "titles": "Standard 1",
          "group": "Number (%) includedb"
        },
        {
          "titles": "Standard 2",
          "group": "Number (%) includedb"
        },
        {
          "titles": "Standard 3",
          "group": "Number (%) includedb"
        }
      ],
      "rows": [
        [
          "Brazil (EVAL)",
          "266",
          "182",
          "180 (99)",
          "180 (99)",
          "180 (99)"
        ],
        [
          "Peru (EVAL)",
          "199",
          "173",
          "173 (100)",
          "173 (100)",
          "173 (100)"
        ],
        [
          "South Africa (EVAL)",
          "259",
          "207",
          "204 (99)",
          "204 (99)",
          "205 (99)"
        ],
        [
          "Vietnam (EVAL)",
          "312",
          "186",
          "186 (100)",
          "186 (100)",
          "186 (100)"
        ],
        [
          "India (DEMO)",
          "619",
          "432",
          "–",
          "403 (93)",
          "421 (98)"
        ],
        [
          "India (RFA)",
          "530",
          "0",
          "–",
          "–",
          "–"
        ],
        [
          "Vietnam (RFA)",
          "503",
          "351",
          "–",
          "–",
          "348 (99)"
        ],
        [
          "Malawi (RFA)",
          "273",
          "0",
          "–",
          "–",
          "–"
        ],
        [
          "United Republic of Tanzania (RFA)",
          "648",
          "489",
          "–",
          "438 (90)",
          "478 (98)"
        ],
        [
          "Uganda (RFA)",
          "233",
          "149",
          "149 (100)",
          "149 (100)",
          "149 (100)"
        ],
        [
          "Côte d’Ivoire (RFA)",
          "500",
          "329",
          "–",
          "–",
          "305 (93)"
        ],
        [
          "Madagascar (RFA)",
          "548",
          "350",
          "333 (95)",
          "333 (95)",
          "347 (99)"
        ],
        [
          "Haiti (Unpublished)",
          "209",
          "124",
          "124 (100)",
          "124 (100)",
          "124 (100)"
        ],
        [
          "Total",
          "5 099",
          "2 972",
          "1 349 (45)",
          "2 190 (74)",
          "2 916 (98)"
        ]
      ],
      "notes": "– Indicates that reference standard criteria were not met by at least 5 TB patients and 5 non-TB patients. DEMO: demonstration study conducted in the setting of intended use; EVAL: evaluation study conducted in a reference laboratory; RFA: request for application. a The total number eligible includes those with missing or indeterminate TB-LAMP results: Brazil EVAL (n = 2 indeterminate), South Africa EVAL (n = 2 indeterminate), Madagascar RFA (n = 1 indeterminate), United Republic of Tanzania RFA (n = 6 missing). b All reference standards classify patients as having TB if ≥ 1 positive culture was confirmed as M. tuberculosis by speciation testing. To be classified as not having TB, patients were required to have no positive and at least (i) two negative cultures on two different sputum specimens (Standard 1), (ii) two negative cultures on the same or different sputum specimens (Standard 2), or (iii) at least one negative culture (Standard 3).",
      "narratives": {
        "en": "For the analysis of TB-LAMP as an add-on test after negative sputum-smear microscopy, the table gives for each of the 13 study sites the total number of participants, the number eligible and the number (%) included under each of three culture-based reference standards, with totals.",
        "ar": "بالنسبة لتحليل اختبار TB-LAMP كاختبار إضافي بعد فحص مجهري سلبي للطاخة البلغم، يعرض الجدول لكل موقع من مواقع الدراسة الثلاثة عشر العدد الإجمالي للمشاركين، وعدد المؤهلين، وعدد (نسبة) المدرجين وفق كل معيار من المعايير المرجعية الثلاثة القائمة على الزرع، مع المجاميع.",
        "zh": "针对在痰涂片显微镜检查阴性后以TB-LAMP作为附加检测的分析，本表按13个研究地点分别列出参与者总数、符合条件人数，以及在三种基于培养的参考标准下各自纳入的人数（%），并给出合计。",
        "es": "Para el análisis de la TB-LAMP como prueba complementaria tras una baciloscopia de esputo negativa, el cuadro indica para cada uno de los 13 centros de estudio el número total de participantes, el número de elegibles y el número (%) de incluidos según cada uno de los tres patrones de referencia basados en el cultivo, con los totales.",
        "fr": "Pour l’analyse du TB-LAMP en tant que test complémentaire après une microscopie des frottis d’expectoration négative, le tableau indique pour chacun des 13 sites d’étude le nombre total de participants, le nombre de participants éligibles et le nombre (%) inclus selon chacune des trois normes de référence fondées sur la culture, avec les totaux.",
        "ru": "Для анализа TB-LAMP в качестве дополнительного теста после отрицательной микроскопии мазка мокроты в таблице по каждому из 13 исследовательских центров приведены общее число участников, число соответствующих критериям и число (%) включённых по каждому из трёх эталонных стандартов на основе посева, а также итоговые значения."
      },
      "csv": "tables/table-6.csv"
    },
    {
      "label": "Table 7",
      "caption": "Table 7. TB-LAMP as an add-on test following smear microscopy: pooled sensitivity and specificity",
      "pages": [
        34
      ],
      "columns": [
        {
          "titles": "Reference standarda"
        },
        {
          "titles": "Pooled sensitivityb"
        },
        {
          "titles": "Pooled specificityb"
        }
      ],
      "rows": [
        [
          "Standard 1",
          "42.1 (30.0-55.3)",
          "98.4 (95.9-99.4)"
        ],
        [
          "Standard 2",
          "42.2 (27.9-57.9)",
          "98.0 (96.0-99.0)"
        ],
        [
          "Standard 3",
          "40.3 (27.9-54.0)",
          "97.7 (96.1-98.6)"
        ]
      ],
      "notes": "a All reference standards classify patients as having TB if ≥ 1 positive culture was confirmed as M. tuberculosis by speciation testing. To be classified as not having TB, patients were required to have no positive and at least (i) two negative cultures on two different sputum specimens (Standard 1), (ii) two negative cultures on the same or different sputum specimens (Standard 2), or (iii) at least one negative culture (Standard 3). b Values are percentages (95% confidence intervals).",
      "narratives": {
        "en": "The table gives the pooled sensitivity and specificity, as percentages with 95% confidence intervals, of TB-LAMP used as an add-on test following smear microscopy against each of three culture-based reference standards.",
        "ar": "يعرض الجدول الحساسية والنوعية المجمعتين، كنسب مئوية مع فترات ثقة 95%، لاختبار TB-LAMP المستخدم كاختبار إضافي بعد الفحص المجهري للطاخة، مقارنةً بكل معيار من المعايير المرجعية الثلاثة القائمة على الزرع.",
        "zh": "本表列出了在涂片显微镜检查后以TB-LAMP作为附加检测时，相对于三种基于培养的参考标准的合并敏感度和特异度（百分比及95%置信区间）。",
        "es": "El cuadro presenta la sensibilidad y la especificidad agrupadas, en porcentajes con intervalos de confianza del 95%, de la TB-LAMP utilizada como prueba complementaria tras la baciloscopia, frente a cada uno de los tres patrones de referencia basados en el cultivo.",
        "fr": "Le tableau présente la sensibilité et la spécificité poolées, en pourcentages avec intervalles de confiance à 95 %, du TB-LAMP utilisé comme test complémentaire après la microscopie des frottis, par rapport à chacune des trois normes de référence fondées sur la culture.",
        "ru": "В таблице приведены объединённые чувствительность и специфичность (в процентах с 95% доверительными интервалами) TB-LAMP, используемого в качестве дополнительного теста после микроскопии мазка, по сравнению с каждым из трёх эталонных стандартов на основе посева."
      },
      "csv": "tables/table-7.csv"
    },
    {
      "label": "Table 8",
      "caption": "Table 8. Diagnostic accuracy of TB-LAMP compared with the Xpert MTB/RIF assay: eligible and included patients, by reference standard and study site. (See Annex 1 for information about the studies)",
      "pages": [
        35
      ],
      "columns": [
        {
          "titles": "Study"
        },
        {
          "titles": "Total number of participants"
        },
        {
          "titles": "Number of participants eligiblea"
        },
        {
          "titles": "Standard 1",
          "group": "Number (%) includedb"
        },
        {
          "titles": "Standard 2",
          "group": "Number (%) includedb"
        },
        {
          "titles": "Standard 3",
          "group": "Number (%) includedb"
        }
      ],
      "rows": [
        [
          "Brazil (EVAL)",
          "266",
          "–",
          "–",
          "–",
          "–"
        ],
        [
          "Peru (EVAL)",
          "199",
          "190",
          "190 (100%)",
          "190 (100%)",
          "190 (100%)"
        ],
        [
          "South Africa (EVAL)",
          "259",
          "238",
          "237 (99%)",
          "237 (99%)",
          "238 (100%)"
        ],
        [
          "Vietnam (EVAL)",
          "312",
          "–",
          "–",
          "–",
          "–"
        ],
        [
          "India (DEMO)",
          "619",
          "–",
          "–",
          "–",
          "–"
        ],
        [
          "India (RFA)",
          "530",
          "–",
          "–",
          "–",
          "–"
        ],
        [
          "Vietnam (RFA)",
          "503",
          "344",
          "–",
          "–",
          "342 (99%)"
        ],
        [
          "Malawi (RFA)",
          "273",
          "258",
          "–",
          "148 (57%)",
          "232 (90%)"
        ],
        [
          "United Republic of Tanzania (RFA)",
          "648",
          "630",
          "–",
          "581 (92%)",
          "625 (99%)"
        ],
        [
          "Uganda (RFA)",
          "233",
          "190",
          "184 (97%)",
          "189 (99%)",
          "190 (100%)"
        ],
        [
          "Ivory Coast (RFA)",
          "500",
          "480",
          "–",
          "–",
          "451 (94%)"
        ],
        [
          "Madagascar (RFA)",
          "548",
          "507",
          "464 (92%)",
          "464 (92%)",
          "504 (99%)"
        ],
        [
          "Haiti (Unpublished)",
          "209",
          "–",
          "–",
          "–",
          "–"
        ],
        [
          "Total",
          "5 099",
          "2 837",
          "1 075 (38%)",
          "1 809 (64%)",
          "2 772 (98%)"
        ]
      ],
      "notes": "– Indicates that reference standard criteria were not met by at least 5 TB patients and 5 non-TB patients. DEMO: demonstration study conducted in the setting of intended use; EVAL: evaluation study conducted in a reference laboratory; RFA: request for application. a The total number eligible includes only those patients with positive or negative TB-LAMP and Xpert MTB/RIF results. b All reference standards classify patients as having TB if ≥ 1 positive culture was confirmed as M. tuberculosis by speciation testing. To be classified as not having TB, patients were required to have no positive and at least (i) two negative cultures on two different sputum specimens (Standard 1), (ii) two negative cultures on the same or different sputum specimens (Standard 2), or (iii) at least one negative culture (Standard 3).",
      "narratives": {
        "en": "For the comparison of TB-LAMP with the Xpert MTB/RIF assay, the table gives for each of the 13 study sites the total number of participants, the number eligible and the number (%) included under each of three culture-based reference standards, with totals.",
        "ar": "بالنسبة لمقارنة اختبار TB-LAMP مع اختبار Xpert MTB/RIF، يعرض الجدول لكل موقع من مواقع الدراسة الثلاثة عشر العدد الإجمالي للمشاركين، وعدد المؤهلين، وعدد (نسبة) المدرجين وفق كل معيار من المعايير المرجعية الثلاثة القائمة على الزرع، مع المجاميع.",
        "zh": "针对TB-LAMP与Xpert MTB/RIF检测的比较，本表按13个研究地点分别列出参与者总数、符合条件人数，以及在三种基于培养的参考标准下各自纳入的人数（%），并给出合计。",
        "es": "Para la comparación de la TB-LAMP con la prueba Xpert MTB/RIF, el cuadro indica para cada uno de los 13 centros de estudio el número total de participantes, el número de elegibles y el número (%) de incluidos según cada uno de los tres patrones de referencia basados en el cultivo, con los totales.",
        "fr": "Pour la comparaison du TB-LAMP avec le test Xpert MTB/RIF, le tableau indique pour chacun des 13 sites d’étude le nombre total de participants, le nombre de participants éligibles et le nombre (%) inclus selon chacune des trois normes de référence fondées sur la culture, avec les totaux.",
        "ru": "Для сравнения TB-LAMP с тестом Xpert MTB/RIF в таблице по каждому из 13 исследовательских центров приведены общее число участников, число соответствующих критериям и число (%) включённых по каждому из трёх эталонных стандартов на основе посева, а также итоговые значения."
      },
      "csv": "tables/table-8.csv"
    },
    {
      "label": "Table 9",
      "caption": "Table 9. Accuracy of TB-LAMP and the Xpert MTB/RIF assay: pooled sensitivity and specificity",
      "pages": [
        36
      ],
      "columns": [
        {
          "titles": "Reference standarda"
        },
        {
          "titles": "Pooled sensitivityc"
        },
        {
          "titles": "Pooled specificityc"
        }
      ],
      "rows": [
        [
          "TB-LAMPb",
          "",
          ""
        ],
        [
          "Standard 1",
          "78.0 (66.6-86.4)",
          "98.9 (97.4-99.6)"
        ],
        [
          "Standard 2",
          "74.1 (64.1-82.2)",
          "98.8 (96.8-99.6)"
        ],
        [
          "Standard 3",
          "75.8 (63.2-85.0)",
          "98.2 (96.0-99.2)"
        ],
        [
          "Xpert MTB/RIFb",
          "",
          ""
        ],
        [
          "Standard 12",
          "81.1 (70.6-88.5)",
          "98.2 (95.9-99.2)"
        ],
        [
          "Standard 22",
          "80.4 (73.4-85.9)",
          "97.4 (94.9-98.7)"
        ],
        [
          "Standard 32",
          "84.0 (75.6-90.0)",
          "97.2 (94.4-98.6)"
        ]
      ],
      "notes": "a Data were restricted to study participants for whom there were valid results for both TB-LAMP and the Xpert MTB/RIF assay and cases in which testing was performed on non-frozen specimens. b All reference standards classify patients as having TB if ≥ 1 positive culture was confirmed as M. tuberculosis by speciation testing. To be classified as not having TB, patients were required to have no positive and at least (i) two negative cultures on two different sputum specimens (Standard 1), (ii) two negative cultures on the same or different sputum specimens (Standard 2), or (iii) at least one negative culture (Standard 3). c Values are percentages (95% confidence intervals). The superscript “2” after Standard 1–3 in the Xpert MTB/RIF rows is printed as shown; it has no matching footnote.",
      "narratives": {
        "en": "The table compares the pooled sensitivity and specificity, as percentages with 95% confidence intervals, of TB-LAMP and the Xpert MTB/RIF assay against each of three culture-based reference standards, among participants with valid results for both tests on non-frozen specimens.",
        "ar": "يقارن الجدول الحساسية والنوعية المجمعتين، كنسب مئوية مع فترات ثقة 95%، لاختبار TB-LAMP واختبار Xpert MTB/RIF مقارنةً بكل معيار من المعايير المرجعية الثلاثة القائمة على الزرع، لدى المشاركين الذين حصلوا على نتائج صحيحة للاختبارين على عينات غير مجمدة.",
        "zh": "本表比较了TB-LAMP与Xpert MTB/RIF检测相对于三种基于培养的参考标准的合并敏感度和特异度（百分比及95%置信区间），对象为两种检测在非冷冻标本上均有有效结果的参与者。",
        "es": "El cuadro compara la sensibilidad y la especificidad agrupadas, en porcentajes con intervalos de confianza del 95%, de la TB-LAMP y la prueba Xpert MTB/RIF frente a cada uno de los tres patrones de referencia basados en el cultivo, en participantes con resultados válidos de ambas pruebas en muestras no congeladas.",
        "fr": "Le tableau compare la sensibilité et la spécificité poolées, en pourcentages avec intervalles de confiance à 95 %, du TB-LAMP et du test Xpert MTB/RIF par rapport à chacune des trois normes de référence fondées sur la culture, chez les participants ayant des résultats valides aux deux tests sur des échantillons non congelés.",
        "ru": "В таблице сравниваются объединённые чувствительность и специфичность (в процентах с 95% доверительными интервалами) TB-LAMP и теста Xpert MTB/RIF по отношению к каждому из трёх эталонных стандартов на основе посева у участников с валидными результатами обоих тестов на незамороженных образцах."
      },
      "csv": "tables/table-9.csv"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 32,
      "note": "inferred"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 33,
      "note": "2 levels"
    },
    {
      "kind": "figures",
      "state": "found",
      "count": 15
    },
    {
      "kind": "tables",
      "state": "found",
      "count": 9
    },
    {
      "kind": "references",
      "state": "none",
      "note": "no such heading in the text"
    },
    {
      "kind": "glossary",
      "state": "not-extracted",
      "note": "a glossary section is in the text (p1); its entries are not extracted"
    },
    {
      "kind": "footnotes",
      "state": "not-extracted"
    },
    {
      "kind": "summaries",
      "state": "partial",
      "count": 30,
      "note": "30 of 33 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-249154"
  }
}
